

FACULDADE DE MEDICINA DA UNIVERSIDADE DE COIMBRA

MESTRADO INTEGRADO EM MEDICINA – TRABALHO FINAL

RITA ADELAIDE GONÇALVES AZEVEDO

Effects of creatine supplementation in older adults

SYSTEMATIC REVIEW

ÁREA CIENTÍFICA DE GERIATRIA

Trabalho realizado sob a orientação de:

PROF. DRº MANUEL TEIXEIRA MARQUES VERÍSSIMO

DRº HELDER FILIPE DA CUNHA ESPERTO

MARÇO/2017

FACULDADE DE MEDICINA DA UNIVERSIDADE DE COIMBRA

Effects of creatine supplementation in older adults

Rita Adelaide Gonçalves Azevedo 1 Manuel Teixeira Marques Veríssimo 2, 3 Helder Filipe da Cunha Esperto 2, 3

1. Mestrado Integrado em Medicina – Faculdade de Medicina, Universidade de Coimbra, Portugal

- 2. Docência Faculdade de Medicina, Universidade de Coimbra, Portugal
- 3. Centro Hospitalar da Universidade de Coimbra, Coimbra, Portugal

Rita Adelaide Gonçalves Azevedo Correio eletrónico: rita.a.azevedo@gmail.com

ABSTRACT

Introduction: The age-related muscle and bone loss have a negative impact on the quality of life of older adults once they lead to a decrease of the ability to perform daily living tasks. Supplements for older adults are currently use in clinical practice. The purpose of this systematic review was to determine which are the effects of creatine supplementation in older adults.

Methods: MedLine, Embase and Cochrane databases were searched. Randomized placebo control trials, prospective observational studies with controls, retrospective matched-pair studies, and comparative studies involving supplementation with creatine in older adults (\geq 65 years) were considered. Additional articles were retrieved from reference lists found in these papers. Quality of the studies was evaluated by using Jadad Scale.

Results: 28 studies respecting the inclusion and exclusion criteria were selected for this systematic review with a total of 836 subjects taking part in the studies. There was a great diversity across the studies in terms of the participants included (healthy, COPD, Parkinson, rheumatoid arthritis, post total joint arthroplasty, ongoing chemotherapy for colorectal cancer), supplementation strategies (differences in types of creatine, doses and additional protein supplementation), exercise training (type, frequency), design (duration, setting) and Jadad score (from 1 to 5).

Discussion: Evidence suggests that body mass and fat free mass might beneficiate from creatine supplementation when it is conducted during a short period or for a moderate period combined with training. The effects of supplementation on muscular function seemed to be benefic, nevertheless it is not clear if creatine only improves the effects of training or if it has beneficial effects itself. The lack of evidence on COPD, Parkinson, rheumatoid arthritis patients and on safety issues prevents the author to make conclusions on those.

Conclusion: Further studies are needed to determine whether creatine is effective in the absence of training, which are the optimal doses of supplementation and to clarify the safety of the supplement in older adults.

Keywords: Creatine, Supplementation, Aged

INTRODUCTION

When there is a low dietary creatine (CR) uptake, mostly because of the small intake of meat and fish, CR is synthesized from arginine, glycine, and methionine in the kidneys, liver, and pancreas (1,2). Via a sodium-dependent creatine transporter, CR is stored in skeletal muscle, heart and brain where it plays an important role in the energy metabolism. CR is a component of phosphocreatine, a high-energy phosphate, which is needed to resynthesize adenosine diphosphate (ADP) to maintain adenosine triphosphate (ATP) during intense muscle contraction (i.e. PCr + ADP <-> ATP + Cr). (3–5)



Figure 1 *Creatine metabolism.* Reproduced from Bogdanis, G. C., A. Papaspyrou, and M. Maridaki. "Muscle metabolism and fatigue during sprint exercise: effects of creatine supplementation." Serbian Journal of Sports Sciences 1.2 (2007): 37-57.

Muscle loss, known as sarcopenia, along with loss of strength (dynapenia) and reduction in bone mass are some of the biological changes that are widely known to be related with aging and they are associated with poorer health outcomes, including obesity, osteoporosis and type 2 diabetes. (6–8) Along with that, some authors suggest that diseases as Chronic Obstructive Pulmonary Disease (COPD) (9) and Parkinson (10) are more frequent in older than in younger ages.

Once aging is strongly related with the risk of falls and depression, which determine a lower quality of life, it is a widely recognize health issue. In addition, the number of hospital admissions of older adults are getting higher, consequently increasing health care costs. (11,12)

Many studies have concluded that supplementation with CR can enhance muscle strength, exercise tolerance and fat free mass among young people, making CR one of the most used ergogenic supplements among athletes. (13–15) Lately, research investigating the clinical use of CR among older adults has demonstrated that this supplementation might be beneficial. (3,16–

18) However, the safety of CR among older populations has been concerning scientists and doctors, particularly about its renal effects. (16)

This Systematic Review evaluates the benefits and adverse effects of CR supplementation in older people. The author included RCTs conducted on older adults using CR supplements with or without protein supplements along with or without resistance training. In most of the studies Placebo (PL) was used on the control group (17–43) except for one study that used no intervention in the control group. (44) One of the studies was part of a larger clinical trial so it didn't have a control group. (45) Effects on body composition, diet, muscle function, pulmonary function, cognitive function, mental status, Unified Parkinson's Disease Rating Scale (UPDRS) scores, liver and renal function were assessed.

METHODS

The author summarized all the data known about the effects of CR supplementation in older adults in order to determine whether CR might be or not a good supplement to attenuate the sarcopenic changes of aging, if it can work as an adjuvant therapy of diseases such as COPD, Parkinson or rheumatoid arthritis, and whether there are negative effects of its use. In order to get conclusions about this matter, author analyzed randomized-placebo-control trials, prospective observational studies with controls, retrospective matched-pair studies, and comparative studies conducted in older adults using CR as an intervention along or not with resistance training and protein supplements (PR). Pre and post supplementation data were compared inside and between groups. Outcomes measured were body composition, diet, muscle function, cognitive function, mental status, pulmonary function, UPDR scores, liver and renal function. Finally, in order to formulate conclusions about the effects of supplementation, period of CR use was divided in three different groups: short period (0-<2weeks), moderate period (2weeks-<24) weeks and long period (\geq 24 weeks).

Search and study selection

A comprehensive literature search was made using PubMed MEDLINE, EMBASE and Cochrane Library databases in October 2016. The search was limited to articles conducted only in humans, written in English, Portuguese, Spanish or French and published in the past twenty years (1996-2016). Mesh terms "Creatine", "Dietary supplementation", "Aged", "Older adults" were used in the Pubmed search. The complete electronic search string is provided in supplementary table **S1**. Additional papers were identified through reference search in the selected articles and past reviews.

After duplicate deletion, two investigators independently screened titles and abstracts. Articles were excluded if both investigators agreed an eligibility criteria were met (**table 1**). A second review of the full-text articles was made; differences concerning article inclusion were resolved by consensus discussion.

Data collection

The data was extracted by the author to a Microsoft Excel spreadsheet using a form validated by the investigators. A second investigator confirmed the information collected. The data collected consisted in the following items: study author and date, sample size, participants' characteristics (mean age, sex, disease-specific group), type and duration of intervention and outcomes. The outcomes were pooled into similar subgroups and evaluated together for optimization of the analysis.

Two investigators independently assessed the quality of the studies using the Jadad Scale. (46) Differences were resolved by consensus. The results were not used to exclude any article.

Table 1. Study Inclus	ion and Exclusion Criteria								
	Inclusion Criteria	Exclusion Criteria							
Population	Adults (mean age \geq 60yr)								
Interventions	CR supplementation with or without	Additional interventions (eg:							
	protein supplementation, with or without	linoleic acid). Use of CR lesser							
	training exercise	than 5 days							
Comparisons of	Control groups using placebo. Control								
interest	groups with no intervention								
Outcomes measured	At least one of the following outcomes	Other outcomes							
	measured: body composition, exercise								
	performance, physical rehabilitation,								
	nutrition status and cognitive functioning								
	in older adults								
Study design	RCT's. Due to the small number of	Studies with no comparator							
	RCT's, prospective observational studies group (for example, cas								
	vith controls, retrospective matched-pair series); non-matched								
	studies, and comparative studies were	retrospective studies and chart							
	also included	reviews							
CR, Creatine, RCT, Ra	andomized clinical trials	·							

RESULTS

The initial search yielded **450 articles**. After duplication removal **343** relevant citations were screened. **50** studies were left for resolving conflicts that were decided by the two investigators together, and according to the inclusion and exclusion criteria, 25 studies from the 50 were retrieved for full text review. **Three** studies found by hand search by the author were posteriorly add for full text review. At the end, **28** studies were selected for full text review. The flow of studies through the review process is summarized in **Figure 1**. Details of the 28 included studies can be found in **table 2**.



Figure 2 Flow through of articles through the search and review process.

8

The studies involved a total of 836 subjects, ranged in sample size from 12(35) to 80 (28) participants and varied in duration between 5 days (35,38,43) and 2 years. (21) Of these studies 13 only included two comparison groups (CR or PL) without any other intervention. (21,24,32,33,35–43) In 15 studies participants went in a training program (18–20,22,23,25–31,34,44,45) and 3 of these studies also used protein as a supplement along with CR. (23,44,45) The majority of these studies (12 out of 15) used resistance training as training program (18–20,22,23,25,26,29,34,44,45) and 3 used a specific Pulmonary Rehabilitation program. (28,30,31) Creatine monohydrate was the mostly used supplementation (18–20,22–24,27–29,31–35,37–40,42–44), Di-Creatine-Citrate was used by one study (41) and 6 studies did not specify the type of CR used. (21,25,26,30,36,45) The doses of CR supplementation varied from single dose of 5 grams per day (19,22,29,35,36) to 20 grams per day. (17) Most of the studies used a loading dose followed by a lower dose for the remain of the trial: 8 used a loading dose for 5 days (18,20,25,26,28,34,42,44), 4 for 7 days (27,30,37,41), 2 for 10 days (39,40), 1 for 14 days (31) and 1 one for 6 months. (21) These data is presented in **table 2**.

Study population groups included healthy older subjects (22,36,41), older men (23,25–27,29,35,38,39,43,44), older women (19,24,33,34), subjects with frailty (45), vulnerable older women (34), COPD (28,30,31), Parkinson (18,21), ongoing chemotherapy of colorectal cancer (37), recovering of total joint arthroplasty (40) and rheumatoid arthritis. (42)

Using the Jadad Scale, investigators scored 4 studies with the total score of 5 (20,28,34,42), 13 with the score of 4 (19,22-24,26,27,30-32,37,38,40), 8 were qualified with the total score of 3 (18,21,29,33,35,39,41,45), another 2 was given the total score of 2 (43,44) and 1 study had 1 point for the total score. (36) The Jadad Scale table is presented on supplementary table **S2**.

Table 2.	Details of t	he incluc	led studies regard	ding subj	ject charad	cteristic	s, creatine	and protein supplementation p	rotocol a	nd training	
Author/y ear	Study design	Mean age (SD)	Sample size	% males	Populati on	Duran tion)	Interventi on	Creatine (dose)	Protein (dose)	Placebo (dose)	Exercise type, Duration (sessions/week)
Aguiar A.F. 2012	RCT	(5)679	CR=9 PL=9	%0	Older women	24	Creatine + Training	CrM+dextrose= 5g+2g/d	1	Dextrose=7g/d	Resistance, 3 sessions/w for the last 12w
Alves, C. et al 2013	RCT	66.9 (4.9)	CR=13 PL=12 CR+TR=12 PL+TR=10	%0	Older women	24	Creatine + Training	CrM=20g/d for 5d followed by 5g/d	<u>r</u>	Dextrose= 20g/d for 5d followed by 5g/d	Resistance, 2s/w
Bender, A et al 2008	Randomize d Pilot Trial	60 (9.4)	CR=40 PL=20	CR=71 % PL=78 %	Parkinso n Disease	96	Creatine	Cr=20g/d for 6d followed by 2g/d for 6m and 4g/d	1	2	1
Brose A. Et al 2003	RCT	68.7(4. 8)	CR=14 PL=14	CR=57 % PL=50 %	Older adults	14	Creatine + Training	CrM+dextrose=5g+2g/d	<u>ņ</u>	Dextrose=7g/d	Resistance, 3 s/w
Candow, D. et al 2008	RCT	65.6(2. 7)	CrP=10 CR=12 PL=12	100%	Older Men	10	Creatine + Protein + Training	CrM= 0.1 g/kg/D	Protein= 0.3 g/kg/d	Chocolate and Cherry- flavored sucrose powder =1.2 g/kg	Resistance 3s/w
Cañete, S et al 2006	Single- blind design	68(4)	CR=10 PL=6	%0	Older Women	-	Creatine	CrM=0,3g/kg x3/d for 7d	<u>n</u>	Powdered Cellulose=0.3G/Kg x3/d for 7d	1
Chilibeck , P. D. et al 2005	RCT	70(6.6)	CR=16 PL=13	100%	Older Men	12	Creatine + Training	Cr=0.3g/d 1st 5d followed by 0.07g/d	1	Sucrose Fluor Mixture=0.3g/d 1st 5d followed by 0.07g/d	Resistance, 3 s/w
Chrusch, M. et al 2001	RCT	70.4(1. 6)	CR=16 PL=14	100%	Older Men	12	Crreatine + Training	Cr+sucrose=0.3 g/kg/d for the first 5d followed by 0.07 g/kg/d	<u>n</u>	Sucrose Fluor Mixture=0.3g/d for the first 5d followed by 0.07g/d	Resistance , 3s/w
Collins, J. et al 2015	Small-scale exploratory trial	70.33(?)	CR+PR=9 PR=7	ċ	Older adults	14	Creatine + Protein + Training	61	ė	i	Resistance, 2s/w

Resistance, 3s/w	Pulmonary rehabilitation, 21 s/7w	Endurance + Resistance, 2-3 s/w	Pulmonary Rehabilitation, 2 s/w	Pulmonary Rehabilitation, 2s/w	1	Ç.	Resistance, 2 s/w	Resistance Training=2 sessions/w	ı
CHO= 20 g of glucose only for 7 days followed by 5 g of glucose on training days	Lactose=24g/d for 5d followed by 4g/d during pulmonary rehabilitation	C.	Glucose= ?	Glucose polymer= 40.7g 3xday for 14 days followed by 40.7g 1xday for 10 weeks	Celulose powder=0.3 g/kg	Celulose powder=??	Dextrose=20g/day for 5 days followed by single daily doses of 5g	Lactose Monohydrate= 20g for the first 5d followed by 5g/d	Maltodextrin= 5g/d
Û	i	I.	1	i.	1	Ĩ.	1	i.	1
CrM+CHO= $20 \text{ g} + 5 \text{ g}$ /d for 7 days followed by 0.1 g/kg/d of crM + 5 g/d of glucose on training days	CrM=22g/d for 5d followed by 3.76g/d during pulmonary rehabilitation	CrM=5g/d	CR?=0.3g/kg/d during 7d followed by 0.07g/kg/d during the remaining 7 weeks	CrM + glucose= 5g+35g 3xday for 14 days followed by 5g+35 1xday for 10weeks	CrM= 0.3G/KG	CrM=0.3 g/kg/d	CrM=20g/d for 5 days followed by single daily dose of 5g	CrM= 20g for the first 5d followed by 5g/d f	CrM + Maltodextrin= 5g/d
Creatine + Training	Creatine + Training	Creatine + Training	Creatine + Training	Creatine + Training	Creatine	Creatine	Creatine + Training	Creatine + Training	Creatine
12	٢	12m	ø	12		-	24	ц	7
Older men	COPD	Older Men	COPD	COPD	Older Men	Older Women	Vulnerab le Older Women	Parkinso n Disease	Older Men
100%	CR=50 % PL=74 %	100%	CR=46 % PL=40 %	C-	100%	%0	%0	85%	100%
CR= 10 PL=10	CR=38 PL=42	CR=15 PL=21	CR=13 PL=10	CR=14 PL=11	CR=10 PL=8	CR=15 PL=12	CR=15 PL=15 CR+TR=15 PL+TR=15	CR=10 PL=10	CR=7 PL=5
61.4 (5.0)	68.2(8. 2)	65.3(1. 3)	66.0(6. 0)	61.7(8. 0)	65.4(1. 5)	63.3(1. 2)	66.1 (4.8)	68.1(3. 8)	72.0(2. 0)
RCT	RCT	RCT	RCT	RCT	RCT	RCT	RCT	RCT	RCT
Cooke, M. B. et al 2014	Deacon, S.J. et al 2008	Eijnde, B.O. et al 2003	Faager, G. et al 2006	Fuld, J.P. et al 2005	Gotshalk L.V.J., et al 2002	Gotshalk L.V.J., et al 2008	Gualano, B. et al 2014	Hass, C. J. et al 2007	Jakobi, J.M. et al 2001

McMorri s et al 2007	Norman, K. et al 2006	Rawson, E.S. et al 1999	Rawson E.S. et al 2000	Roy, B.D. et al 2005	Stout, J.R. et al 2007	Villanuev a, M.G. 2014	Wilkinso n, T.J. et al 2016	Wiroth J.B. et al 2001
RCT	RCT	RCT	RCT	RCT	Double blind cross-over design	RCT	RCT	RCT
76.4 (8.48)	65.1 (12.55)	66.7 (1.9)	65.0(2. 1)	63.3(1 0.2)	74.5(6. 4)	68.1(6. 1)	63.0(1 0.0)	69.4(?)
CR=15 PL=17	CR=16 PL=15	CR=10 PL=10	CR=9 PL=8	CR=18 PL=19	7 male + 8 female	PR+TR=7 TR=7 C=8	CR=15 PL=20	CRsedentary=7 PLsedentary=7 Cttrained=7 Pltrained=7
CR=53 % PL= 47%	CR=62, 5% PL=66, 7%	100%	100%	CR=50 % PL=42 %	47%	100%	CR=23 % PL= 30%	100%
Older subjects	Colorecta 1 Cancer	Older Men	Older Men	Total joint arthropla sty	Older subjects	Older Men	Rheumat oid Arthritis	Older men
2	oo	4	∀	9	7	12	13	∇
Creatine	Creatine	Creatine	Creatine	Creatine	Creatine	Creatine + Protein + Training	Creatine	Creatine
PL= 5g/d followed by CrM=5g/d	CrM= 20g/d in the first week followed by 10g/d	CrM + dextrose= 20g+38g/d during 10 days, followed by 4g+6.8g	CrM+sucrose= 20g+4g/d	CrM+dextrose= 10g+8g d on the 10d before surgery and 5g+4g/d for 30d after surgery	Di-Creatine-Citrate=20g/d during week 1 and 10g/d week 2	CrM= 0.3g/kg/d for 5d followed by 0.07g/kg/d	CrM= 20g/d for the initial 5d followed by 3g/d	CrM+sucrose=15g+ 30g/d
а	I.	а	I.	a	1	Liquid protein= 35g/d	E	1
Maxijoule?= 5g/d	Cellulose=20g/d in the first week followed by 10g/d	Dextrose= 25g/d for 10d followed by 20g dextrose	PL =equivalent volume of look-alike Sucrose	Dextrose= 14g on 10d before surgery and $7g/d$ for 30d after surgery	Flavored effervescent powder blend	1	Flavored drink powder	Casein+sucrose= 30g+15g/d
1	1	u	1	u	I.	Resistance, 3 s/w	i	ı

BODY COMPOSITION

Body Mass

Even though most of the studies described an increase in body mass after the period of supplementation with CR (19,22,27–33,35,37–39,41–43) only 5 of them stated that the increase was significant (p<0.05). (22,27,32,35,38) From these, 3 studies were performed for a short period. (32,35,38)

Cooke et al (27) demonstrated that PL group also had a significant (p<0.05) increase but the increase in CR group was significantly (p<0.05) higher than PL group. Through the duration of this study participants went through a resistance training program.

In the study conducted by *Roy et al* (40) evaluating the supplementation with CR after total joint arthroplasty the body mass decreased both CR and Pl groups without significant p value.

Fat Free Mass (FFM)

Even though FFM increased with no significant *p* value in 4 studies (33,34,38,40) the increase on FFM was significant in 6 studies with *p* value <0.05 (23,26–28,32) and in 2 studies with *p* value <0.01. (19,31) From these studies 1 was performed in a long period (19), 6 during a moderate period (23,26–28,31,45) and 1 in a short period of time. (32) Nevertheless, in 3 studies FFM increased with no significant *p* value. (33,38,40)

Cooke et al (27) and *Chrusch et al* (26) documented a significant (p<0.05) increase on PL group. Sidelong with *Fuld et al* (31), *Cooke et al* (27) detected that the increase on CR group was significantly (p<0.05) higher than PL group .

Collins et al (45) reported a significant increase in FFM on both CR+PR and PR groups and *Candow et al* (23) observed a significant (p < 0.05) increase in both PL and CR+PR groups.

Rawson et al (39) described a decrease on FFM after the supplementation with CR. No training was used in this study.

Body Fat

Despite the fact most of the studies described a decrease in body fat after the period of supplementation with CR (19,22,26,27,29,32,33,38–40,44) only 2 of them concluded the decrease was significant (p<0.05). (25,29) While one of this studies was performed in a long period (29) the other occurred during a moderate period of time. (26)

Eijnde BO et al (29) described a significant (p<0.05) decrease in both CR and PL groups after 12 months of endurance plus resistance training along with CR supplementation.

Only one study by *Wilkinson et* al (43) described an increase in body fat after CR supplementation, but with no statistical significance.

Bone Mineral Content (BMC)

BMC was noticed to be increased without significant p value after a moderate period of resistance training and CR supplementation. (25) An non-significant increase was noticed in CR+PR and PR groups after a moderate period of training along with supplementation in the study conducted by *Collis J et al.* (45)

Gualano B et al (34) documented a non-significant decrease in BMC after a long period of CR supplementation and training.

Bone Mineral Density (BMD)

Chilibeck et al (25) concluded that the increase of BMD was significant (p<0.05) in both CR and PL groups. There was one study which did not observe changes in BMD (34) and another detected a non-significant increase in both CR+PR and PR groups. (45) In all these studies patients practiced resistance training along with the CR supplementation for a moderate period (25,45) and for a long period. (34)

Muscle Fibers

Even though both studies studying muscle fibers documented an increase in muscle fibers content after CR supplementation the p values were not significant. (22,27) Patients practiced exercise training along with the supplementation for a moderate period of time.

Muscle Creatine

Despite the fact that in studies where biopsy was performed it was detected an increase in muscle CR after CR supplementation and exercise training (22,29) the increase was only significant (p<0.05) in the one performed in a moderate period of time. (22)

Muscle Phosphocreatine

In both *Brose A et* al and *Eijnde BO et* al (22,29) studies a significant (p<0.05) increase in muscle phosphocreatine was documented after supplementation with CR along with training during a moderate (22) and long (30) period of time.

Details regarding body composition are presented on supplementary tables S3.

NUTRIENTS INTAKE

Proteins

Half of the articles studying nutrients intake stated that protein intake increased with nonsignificant p value after CR supplementation (20,23,34) while 2 studies documented a nonsignificant decrease. (27,39) In *Collins J et al* study (45) patients also used PR along with CR supplementation and this group (CR+PR) decreased protein intake without significant p value. (23) *Gualano B et al* (45) compared CR+PR and PR supplementation and both groups increased protein intake with no significant p value.

Carbohydrates

Carbohydrate intake decreased without significance in CR group in three studies in which patients went in a resistance training program. (23,27,34) In *Candow D et al study* (23) patients also used PR supplementation and PR group also noticed a non-significant decrease in carbohydrate intake. Increase in carbohydrates intake was documented by two studies (20,39), one using resistance training along with CR supplementation (20) and one where there was no training. (39) Neither of the studies documented the increase was significant.

Collins J et al revealed a decrease on CR+PR group while PR increase carbohydrate intake. (45)

Fat

While the majority of the studies stated a non-significant decreased of fat intake (20,27,39) two studies investigating fat intake after CR supplementation documented its increase without significant *p* values. (23,34)

Candow D et al (23) noticed a non-significant fat intake increase in CR group while the CR+PR group decreased fat intake without significance.

In *Collins J et al* study (45) CR+PR group decreased fat intake while PR group increased it without significant p values.

Energy

Most of the studies described a non-significant decrease in energy intake after the period of supplementation with CR (23,27,39) and in one of them the comparing group PR also showed a non-significant decrease. (23)

On *Collins J et al* study (45) both CR+PR and PR groups revealed a non-significant decrease on energy intake.

Gualano B et al (34) stated the amount of kilocalories/day increased without significance after 24 weeks of creatine supplementation together with resistance training.

Nutrients intake data is presented on supplementary tables S4.

DYNAMIC AND ISOMETRIC STRENGTH

1RM Bench Press

Even if all the studies describing 1RM Bench Press described an increase after CR supplementation (19,32–34) only in two studies the increase was significant (p<0.05). (19,32) While *Gotshalk LVJ et al* (32) used a short period of supplementation *Aguiar AF et al* (19) performed the study during a long period of time.

In *Villanueva MG et* al study (44) PR was used along with CR supplementation and CR+PR group described a non-significant increase.

1RM Leg Press

1RM Leg Press increased without significance in all the studies after CR supplementation. (20,22,32–34) *Collins J et al* (44) also detected an increase in 1RM Bench Press in CR+PR group.

1RM Knee Extension

Despite the fact that all the studies describing 1RM Knee extension described an increase after CR supplementation (19,22,32) only two studies (19,32) revealed the increase was significant (p<0.05). While *Gotshalk LVJ et al* (32) used a short period of supplementation *Aguiar AF et al* (19) performed the study during a long period of time.

Bench Press Strength

All the studies which evaluated Bench Press Strength revealed a significant (p<0.05) increase in both CR and PL groups. (23,25,26)

Candow et al (23) concluded that also CR+PR group had a significant (p<0.05) increase on bench press strength. Furthermore, they noticed that CR+PR group had a significant (p<0.05) greater increase than CR and PL groups.

All the studies used resistance training along with CR supplementation for a moderate period.

Leg Press Strength

Leg Press Strength evaluation revealed a significant (p<0.05) increase in both CR and PL groups after CR supplementation in all studies which run this test. (23,25,26) All the studies used resistance training along with CR supplementation for a moderate period.

Candow et al (23) also described a significant (p<0.05) increase in CR+PR group and concluded that the increase was significant (p<0.05) greater in CR+PR than CR group.

Handgrip Strength

Although all the studies which evaluated Hangrip Strength revealed an increase after CR supplementation (22,30,37,40,41) it was only significant (p<0.05) in two of the studies. (30,41) *Faager G et al* (30) revealed the significant (p<0.05) increase was also noticed in PL group. *Collins J et al* (45) noticed a significant (p<0.05) increase in hand grip strength in both CR+PR and PR groups.

Two studies from *Gotshalk LVJ et al* with identical characteristics (CR supplementation vs PL supplementation for 7d) but performed separately in different populations (Older Women (33) vs Older Men (32)) evaluated Lower Body Peak Power (LBPP), Lower Body Mean Power (LBMP), Upper Body Peak Power (UBPP) and Upper Body Mean Power (UBMP)

Both studies revealed an increase in LBPP and LBMP being the increases significant (p<0.05) in the study conducted on older men. (32)

LBMP and UBMP also increased in both studies but it was not significant in any group.

Dynamic and isometric strength data is presented on supplementary tables S5.

FUNCTIONAL CAPACITY

Sit Stand test

Despite the fact that all the studies which rolled the sit stand test observed a decrease on the time needed for sit and stand (24,32,33) only two studies documented the decrease was significant. (24,32) All the studies were performed in a short period of time and neither exercise training or protein supplementation were used.

Timed Stands test

Only in *Collins J et al* study (45) there was a significant (p<0.05) increase in the number of repetitions on time stands test in both CR+PR and PR groups. The rest of the studies performing time stands test detected a non-significant increase in the number of repetitions in both CR and PL groups. (34,41,42)

Timed Up to Go test

Collins J et al (45) observed a significant (p<0.05) decrease in PR group while the CR group showed a significant (p<0.05) increase in time that the participants required to complete the test. *Gualano B et al* (34) observed a non-significant decrease in both CR and PL groups in vulnerable older women.

Details regarding functional capacity are presented on supplementary tables S6.

QUALITY OF LIFE, COGNITIVE AND MENTAL OUTCOMES

Three were the studies evaluating the quality of life of the participants. (20,21,37)

Geriatric Depression Scale was used by *Alves C et* al (20) and the author reported that after 24 weeks of intervention, PL and CR groups which went on resistance training had significant (p<0.05) reductions in depression scores when compared with either the PL and CR groups that did not go on resistance program.

Bender A et al (21) used SF-36 scores and detected a non-significant decrease.

Emotional and **social functioning** were evaluated by *Norman K et al* (37) who documented a non-significant increase of these variables in CR group. The same author measured **global health status** and reported a non-significant decrease in CR group.

Minimal Mental State Examination (MMSE) and **Brief Battery of Cognitive Screening** (**BBCS**) were measured by *Alves C et* al (20) who documented a non-significant increased after CR supplementation.

All **memory tests** (random number generation, number recall test forward number, number recall test forward spatial, number recall test backward spatial, long term memory) performed by *McMorris et al* (36) showed an increased after CR supplementation but only the results of number recall test backward spatial and long term memory tests were significant (p<0.01) in CR groups. **Cognitive functioning** measured by *Normal K et al* (37) presented no changes in CR group.

Quality of life, cognitive and mental data is presented on supplementary tables S7.

SPECIFIC DISEASES

<u>COPD</u>

Three studies were conducted in COPD patients who went through a pulmonary rehabilitation program along with CR supplementation for a moderate period of time. (28,30,31)

Deacon SJ et al (28) compared the effects of CR supplementation after the loading phase with the effects shown after pulmonary rehabilitation. After loading phase Body mass, FFM, ISWT (Incremental Shuttle Walking Test), ICQ (Isokinetic Concentric Quadriceps) and IT (Isokinetic Triceps) showed a significant increase with p value <0.01 while IB (Isokinetic Biceps) showed a significant increase with p value <0.05. Once patients went through the pulmonary rehabilitation the values of ESWT (Endurance Shuttle Walking Test), ISWT and IB showed a significant increase with p value <0.01 while FFM, ICQ and IQ showed an increase with p value <0.05.

Faager J et al (30) compared PL and CR groups, both going on pulmonary rehabilitation. Significant increases with p value <0.01 in CR were detected in ESWT and breathing rate and with *p* value <0.05 were detected in BM, Body Mass Index (BMI) and grip strength. PL group significantly increased BM and grip strength with p<0.05 and heart rate with p<0.01. Breathing rate decreased on PL group with *p* value <0.05.

Fuld JP et al (31) compared the CR and PL groups before and after pulmonary rehabilitation. After CR supplementation without pulmonary rehabilitation BM, FFM, Upper Limb Muscle Function (ULMF), peak torque, Lower Limb Muscle Function (LLMF) and time walked showed a significant (p<0.01) increase. Differences between groups were significantly higher in CR group in BM, FFM, ULMF and peak torque with *p* value <0.01 and in LLMF with *p* value <0.05.

While on pulmonary rehabilitation CR group presented a significant increase with p value <0.01 in FFM, ULFM, peak torque, LLMF and time walked. Increase with p value <0.05 was observed in peak force and distance walked. Significant decreases were observed in St George's Respiratory Questionnaire (SGRQ) activity with p value <0.01 and in Incremental Exercise Test (IET) and SGRQ total score with p value <0.05.

After pulmonary rehabilitation PL group showed significant increases in LLM and time walked with p value <0.01 and ULMF, peak torque, distance walked and SGRQ activity with p value <0.05. Differences between groups showed a significant greater increase in CR group with p value <0.05 in FFM, peak force, ULMF, peak torque and LLMF and with p value <0.01 in the time walked. PL group had a significant greater increase with p value <0.05 in distance walked and SGRQ total score and in SGRQ activity with p value <0.01.

Outcomes evaluated simultaneously across the three studies are presented next.

Endurance Shuttle Walking Test (ESWT)

Both *Deacon SJ et al* (28) and *Faager J et al* (30) detected a significant (p<0.01) increase in ESWT values. The increase was also significant (p<0.01) in PL group in *Deacon SJ et al* (28) study.

Fat Free Mass

FFM was estimated using diseased specific regression equations by *Deacon SJ et al* (28) and *Fuld JP et al* (31) and both studies documented a significant increase in CR group with *p value*<0.01 (28) and *p value* <0.05. (32) *Deacon SJ et al* (29) also documented a significant increase in PL group with *p value*<0.05.

Fat Mass

Fat Mass decreased without significant p value after the period of pulmonary rehabilitation combined with CR supplementation on both *Deacon SJ et al* (29) and *Fuld JP et al* (32) studies.

Details regarding COPD data are presented on supplementary tables S8.

Parkinson

Two studies were conducted on Parkinson patients. (18,21) *Hass CJ et al* (18) used resistance training along with CR supplementation and *Bender A et al* (21) had no other intervention besides CR supplementation.

Unified Parkinson's Disease Rating Scale (UPDRS) scores

A significant (p<0.05) decrease in UPDRS motor and total scores in CR group along with a significant (p<0.05) increase in PL group was detected by *Hass CJ et al.* (19) Same authors detected that UPDRS mental and UPDRS Activity of Daily Living (ADL) significantly (p<0.05) increased on both CR and PL groups.

Bender A et al (22) detected a non-significant increase of UPDRS values on both groups.

Levodopa and Agonist doses and SPECT variables

Bender A et al (22) documented the dose of agonist significantly (p<0.05) increased in both CR and PL groups while the dose of levodopa increased in both groups with no significant p value. The same study concluded there was no overall treatment effect on SPECT variables.

Parkinson variables data is presented on supplementary tables S9.

Rheumatoid Arthritis

CR supplementation was study in rheumatoid arthritis patients by *Wilkinson TJ et al* (42) who showed greater significant (p<0.05) increases in CR group than PL group on appendicular lean mass (ALM), total body water (TBW), intracellular water (ICW) and extracellular water (ECW).

SAFETY ISSUES

Renal Function

Plasma creatinine

Most of the studies analyzing plasma creatinine detected its increase after CR supplementation (22,32,33) but only in *Brose A et al* (22) and *Gotshalk LVJ et al* (33) studies the increase was significant (p<0.05). Plasma CR increased from 111.4(24.4) µmols/L to 126.2(33.4) µmols/L (22) and from 89.4(15.7) µmols/L to 97.9(17.8) µmols/L. (32)

Plasma Urea and Blood Urea Nitrogen (BUN)

Plasma Urea was analyzed by two studies. *Collins J et al* (46) detected a non-significant increase after CR+PR and PR supplementation and *Cañete S et al* (25) did not observe changes on plasma urea values.

BUN was analyzed by *Gotshalk LVJ et al* in two different studies. (33,34) In the one performed in older women BUN had a non-significant decrease after CR supplementation (33) while in the one performed in older men authors did not detect changes on its values. (32)

Liver Function

Albumin

While *Cañete S et al* (24) documented no changes on albumin concentration after CR supplementation *Gotshalk LVJ et al* (32) noticed a non-significant decrease. Studies had the same characteristics (CR supplementation vs Placebo for 7d) but while the first was conducted on Older Women, the second was performed on Older Men. (32)

Aspartate Transaminase (AST)

Two studies documented a non-significant decrease on AST values after CR supplementation. (32,33)

Collins J et al (46) documented AST decrease on both CR+PR and PR groups.

Cañete S et al did not detect changes on AST values after CR supplementation. (24)

Alanine Transaminase (ALT)

After CR supplementation, ALT values presented different non-significant changes across the studies: one documented its increase (33), one its decrease (32) and other presented no changes on ALT values. (24) After CR+PR and PR supplementation ALT increased in both groups on *Collins J et al* study. (45)

Gama Glutamil Transferase (GGT)

Two studies evaluating GGT documented its non-significant decrease after CR supplementation (24,32) while one study stated its non-significant increase. (33) After CR+PR GGT increased without significant p values while after PR it decreased also without significance. (45)

Reported Adverse Effects

Few of the studies of this review reported adverse effects of its participants. (22,23,26,32,39) Gastrointestinal distress was reported in four studies which stated it to be higher in CR groups than PL groups. (22,26,32,39) In four studies muscle cramping, soreness and stiffness was documented in both CR and PL

groups. (23,26,32,39)

Skin rash was reported in one participant on CR supplementation. (39)

Safety issues data is presented on supplementary tables S10.

DISCUSSION

MAIN FINDINGS

A careful reading of the articles assessed for eligibility leads the author to a total of 28 studies of older adults (\geq 65 years) in which CR supplementation combined or not with PR supplementation and/or training is used to improve body mass, functional capacity, cognitive performance and COPD, Parkinson and rheumatoid arthritis variables.

Seventeen studies conducted in older adults, using CR monohydrate in a dose varying from 0.1/kg/day to 5g/day evaluated the effects of CR supplementation in body mass. Five studies have shown with significant evidence that short period supplementation with CR and moderate period of supplementation combined with training have positive effects on body mass gain. Studies have shown the increase of FFM with significant evidence when supplementation with CR monohydrate is conducted during a short period and during a moderate to long period of time combined with training. Once PL groups also had significant increases on FFM when training was performed, evidence suggests that the effect of training is greater than the CR supplementation on improving FFM. According to the evidence, body fat seems to decrease after CR supplementation with and without training. Significant p values (<0.05) were found in two studies.

In which refers to body composition, body mass and FFM showed to be increased when the supplementation is rolled either during a short period of time or during a moderate/long period along with resistance training. The use of resistance training seems to have a strong impact on FFM leading the effects of CR hard to be understandable. More investigation about the use of CR to improving FFM without training must be done.

Evidence suggests there are no overall effects of CR supplementation on dietary intake.

The present evidence about dynamic strength suggests that CR monohydrate might be benefic increasing 1RM bench press and 1RM knee extension when it is given during a short period of time or for a long period of time combined with resistance training. However, the evidence about this matter is poor once only 2 and 3 studies evaluating 1RM bench press and 1RM knee extension respectively detected an increase in this outcomes. Leg press strength and bench press strength were evaluated by 3 studies conducted during a moderate period of time combined with resistance training varying the dose of CR from 0.07g/kg/day to 0.1mg/kg/day. The evidence suggests that resistance training might have a greater effect than CR increasing isometric strength once PL groups also demonstrated a significant increase in leg and bench press strength. Three out of 6 studies rolled during a moderate period demonstrated significant increases in handgrip strength in CR groups. Resistance training was used in two of the studies that were not clear about the dose and type of CR used. One of them also demonstrated a significant increase in PL group. According to that, there is not enough evidence to conclude about the benefits of CR

supplementation increasing handgrip strength. Two studies performed for a short period using either 0.3mg/kg/day or 0.9mg/kg/day of CR monohydrate detected a significant decrease on sit stands test on CR groups. According with that, this review failed to demonstrate that CR supplementation for a short period might improve the neuromuscular control under stressful conditions.

Evidence suggests CR supplementation to be a successful supplement improving muscular performance in older adults (≥ 60 years). The evidence is stronger if considered either short period of supplementation or moderate/long period of supplementation combined with resistance training.

Only three studies evaluated the quality of life, social and mental outcomes and the evidence on this matter is not clear to formulate any conclusions. Geriatric depression scale showed significant increases in one study, which make author believe more studies must be done to take any definitive conclusion.

Despite the fact outcomes evaluated by the 3 studies on COPD patients have shown significant increases on CR group variables, most of the times the same results were present on PL groups without significant differences between groups. This leads to the conclusion that pulmonary rehabilitation might be the key to a greater recovery on COPD patients and CR does not appear to increase this effect. Nevertheless, more studies must be done on this matter once the evidence is low giving the number of studies. Studies conducted on Parkinson patients suggest there is no overall effect of CR supplementation. However, evidence on this subject is low once only 2 studies were conducted on these patients. One study on rheumatoid arthritis patients revealed significant improvements on body composition after CR supplementation but as it is the only study on this subject the evidence is very low. Author encourage researchers to study the potential effects of CR supplementation on rheumatoid arthritis patients.

The effects on renal function, evaluated by 4 studies, suggests that CR might increase plasma creatinine once the increase was significant in 2 of the studies which were conducted in a short period of time with a dose of 0.3 mg/kg/day and during a moderate period with a dose of 5 g/day. Plasma CR increased from $111.4(24.4) \,\mu\text{mols/L}$ to $126.2(33.4) \,\mu\text{mols/L}$ (22) and from $89.4(15.7) \,\mu\text{mols/L}$ to $97.9(17.8) \,\mu\text{mols/L}$. (32) Nevertheless, the number of studies going on this matter is small consequently, the evidence is not clear. Liver function seemed to be unchanged after CR supplementation but then again only 4 studies went through this matter leading author to the conclusion that more research must be done on CR safety. Despite the fact that few studies reported adverse effects of CR supplementation it is clear for the author that the most common adverse effect documented is gastrointestinal distress. The period of intervention does not seem to modify the results once the collateral effect was documented on both short and moderate periods of intervention.

LIMITATIONS & STRENGTHS

This study presents a currently issue of interest once worldwide population is getting older and interventions to improve quality of life are increasing its importance. This systematic review is pioneer in evaluating the full spectrum of CR supplementation effects in older adults. Once studies from 5 days to 2 years of intervention were included in this review author is able to conclude about the effects of CR varying on the time of intervention. In order to get a good quality of the review author chose to use PRISMA checklist and to include results of the outcomes measured the same way in at least two studies and present the ones were the differences were significant with p values <0.05 and <0.01.

Only the study conducted by *Wilkinson TJ et* al (43) performed a post-intervention follow up after 12 weeks of the intervention. The rest of the studies included in this systematic review did not perform a follow up of the patients, which makes author unaware of how long the effects of the supplementation were kept. The impact of the co-supplementation with protein is still not clear once few are the studies doing the co-supplementation. (23,44,45) In order to enhance the evidence on the subject more studies must be done on the creatine supplementation combined with protein supplementation in older adults.

Few studies evaluate safety issues of CR supplementation in terms of renal and liver function (22,24,32,33,45) and the reporting of adverse effects is also poor. (22,23,26,32,39) This lack of evidence does not allow the author to make conclusions about CR safety in older adults.

The reduced number of studies evaluating CR effects in specific diseases such as Parkinson and rheumatoid arthritis prevents the author to conclude about the effects of this supplement on improving the conditions of these patients. The author encourages investigators to perform research on CR effects on improving these diseases. Some studies do not provide clearly information about the type (21,25,26,30,45) and dose (45) of CR used. Furthermore, once doses of supplementation are not presented in the same way across the studies the effect of the dose of CR cannot be clearly understand.

Along with the reviews conducted by *Denison H et al* (47) and *Devries M et al* (48) this review suggests beneficial effects of CR combined with training on improving muscular performance in older adults. Additionally, the results of this review support the idea that moderate to long use of CR is no more effective than short supplementation in muscle function improvement if it is not combined with training. The findings of this review prove with moderate evidence that CR supplementation is a potential strategy for the prevention and management of sarcopenia in older adults once there is proof that it improves muscular function. Furthermore, according with the evidence found, CR seems to be a good supplement to improve FFM. Still, author cannot guarantee the good results found on this review are a product of CR supplementation itself or if the supplementation with CR only improves the effects of training.

More research must be done in order to define which cognitive benefits of CR are and which impact they have in the quality of life of older adults. CR showed some positive effects on illnesses as COPD and rheumatoid arthritis still with poor evidence. For that reason, the author believes investigation of the benefits of CR on diseases associated with the process of aging might bring some exciting findings.

The use of CR as a supplement in older adults is not well clarified once the dose to be used and its period of time are not well stablished. Additionally, the insufficient evidence of the safety issues is still preventing the clinical use of CR as supplement to manage the consequences of aging process.

REFERENCES

- Guthmiller P, Van Pilsum JF, Boen JR, McGuire DM. Cloning and sequencing of rat kidney L-arginine:glycine amidinotransferase. Studies on the mechanism of regulation by growth hormone and creatine. J Biol Chem [Internet]. 1994 Jul 1 [cited 2017 Feb 7];269(26):17556–60. Available from: http://www.jbc.org/cgi/content/short/269/26/17556
- Wyss M, Kaddurah-Daouk R. Creatine and Creatinine Metabolism. Physiol Rev. 2000;80(3):1107–213.
- Kuethe F, Krack A, Richartz BM, Figulla HR. Creatine supplementation improves muscle strength in patients with congestive heart failure. Pharmazie [Internet]. 2006;61(3):218–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16599263
- 4. Rawson ES, Venezia AC. Use of creatine in the elderly and evidence for effects on cognitive function in young and old. 2011;1349–62.
- Candow DG, Chilibeck PD. POTENTIAL OF CREATINE SUPPLEMENTATION FOR IMPROVING AGING BONE HEALTH. 2010;14(2):149–53.
- Sayer A., Dennison E, Syddall H, Gilbody H, Phillips D, Cooper C. Type 2 Diabetes, Muscle Strength, and Impaired Physical Function. Diabetes Care. 2005;28(10):2541–2.
- Morley JE, Anker SD, von Haehling S. Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology—update 2014. J Cachexia Sarcopenia Muscle. 2014;5(4):253–9.
- Batsis J a, Mackenzie T a, Barre LK, Lopez-Jimenez F, Bartels SJ. Sarcopenia, sarcopenic obesity and mortality in older adults: results from the National Health and Nutrition Examination Survey III. Eur J Clin Nutr [Internet]. 2014;68(9):1–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24961545
- Disease A, Macnee W. Is Chronic Obstructive Pulmonary Disease an Accelerated. :429– 37.
- Levy G, Review N. The relationship of Parkinson disease with aging. Arch Neurol. 2007;64(9):1242–6.
- Janssen I, Shepard DS, Katzmarzyk PT, Roubenoff R. The Healthcare Costs of Sarcopenia in the United States. J Am Geriatr Soc. 2004;52(1):80–5.
- Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis. Age Ageing. 2010;39(4):412–23.
- Terjung RL, Clarkson P, Eichner R, Greenhaff PL, Hespel PJ, Israel RG, et al. The physiological and health effects of oral creatine supplementation. Med Sci Sports Exerc. 2000;32(3):706–17.

- Rawson ES, D P, Clarkson PM. Scientifically Debatable : Is Creatine Worth Its Weight ? Science (80-). 2003;16(4):1–7.
- Kreider R., Conrad E., Lundberg J. et all. International Society of Sports Nutrition position stand: creatine supplementation and exercise. J Int Soc Sport Nutr. 2007;4(23):1–5.
- 16. Gualano B, Roschel H, Lancha-jr AH, Brightbill CE, Rawson ES. In sickness and in health : the widespread application of creatine supplementation. 2012;519–29.
- Andrews R, Greenhaff P, Curtis S, Perry A, Cowley AJ. The effect of dietary creatine supplementation on skeletal muscle metabolism in congestive heart failure. Eur Hear J [Internet]. 1998;19(4):617–22. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citat ion&list_uids=9597411
- Hass CJ, Collins MA, Juncos JL. Resistance training with creatine monohydrate improves upper-body strength in patients with Parkinson disease: a randomized trial. Neurorehabilitation & Neural Repair [Internet]. 2007;21(2):107–15. Available from: http://proxy-

remote.galib.uga.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db= cin20&AN=2009533119&site=ehost-live

- Aguiar AF, Januário RSB, Junior RP, Gerage AM, Pina FLC, Do Nascimento MA, et al. Long-term creatine supplementation improves muscular performance during resistance training in older women. Eur J Appl Physiol. 2013;113(4):987–96.
- Alves CRR, Merege Filho CAA, Benatti FB, Brucki S, Pereira RMR, de Sá Pinto AL, et al. Creatine Supplementation Associated or Not with Strength Training upon Emotional and Cognitive Measures in Older Women: A Randomized Double-Blind Study. PLoS One. 2013;8(10):1–10.
- 21. Bender A, Samtleben W, Elstner M, Klopstock T. Long-term creatine supplementation is safe in aged patients with Parkinson disease. Nutr Res. 2008;28(3):172–8.
- Brose A, Parise G, Tarnopolsky M a. Creatine supplementation enhances isometric strength and body composition improvements following strength exercise training in older adults. J Gerontol A Biol Sci Med Sci. 2003;58(1):11–9.
- Candow DG, Little JP, Chilibeck PD, Abeysekara S, Zello GA, Kazachkov M, et al. Low-dose creatine combined with protein during resistance training in older men. Med Sci Sports Exerc. 2008;40(9):1645–52.
- 24. Cañete S, San Juan AF, Pérez M, Gómez-Gallego F, López-Mojares LM, Earnest CP, et al. Does creatine supplementation improve functional capacity in elderly women? J Strength Cond Res [Internet]. 2006;20(1):22–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16503684

- 25. Chilibeck PD, Chrusch MJ, Chad KE, Shawn Davison K, Burke DG. Creatine monohydrate and resistance training increase bone mineral content and density in older men. [Internet]. Vol. 9, The Journal of Nutrition, Health & Aging. 2005. p. 352–5. Available from: http://crealift.com.br/wp-content/uploads/2013/10/8.pdf
- Chrusch MJ, Chilibeck PD, Chad KE, Davison KS, Burke DG. Resistance Training in Older Men. Med Sci Sport Exerc. 2001;2111–7.
- 27. Cooke MB, Brabham B, Buford TW, Shelmadine BD, McPheeters M, Hudson GM, et al. Creatine supplementation post-exercise does not enhance training-induced adaptations in middle to older aged males. Eur J Appl Physiol. 2014;114(6):1321–32.
- 28. Deacon SJ, Vincent EE, Greenhaff PL, Fox J, Steiner MC, Singh SJ, et al. Randomized controlled trial of dietary creatine as an adjunct therapy to physical training in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;178(3):233–9.
- 29. Eijnde BO, Van Leemputte M, Goris M, Labarque V, Taes Y, Verbessem P, et al.
 Effects of creatine supplementation and exercise training on fitness in men 55-75 yr old.
 J Appl Physiol [Internet]. 2003;95(2):818–28. Available from: http://jap.physiology.org/content/95/2/818.short
- Faager G, S??derlund K, Sk??ld CM, Rundgren S, Tollb??ck A, Jakobsson P. Creatine supplementation and physical training in patients with COPD: a double blind, placebocontrolled study. Int J Chron Obstruct Pulmon Dis. 2006;1(4):445–53.
- 31. Fuld JP, Kilduff LP, Neder JA, Pitsiladis Y, Lean MEJ, Ward SA, et al. Creatine supplementation during pulmonary rehabilitation in chronic obstructive pulmonary disease. Thorax [Internet]. 2005;60(7):531–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15994258%5Cnhttp://www.ncbi.nlm.nih.gov/pub med/15994258
- 32. Gotshalk L, Volek J. Creatine supplementation improves muscular performance in older men. Med Sci Sport Exerc [Internet]. 2002;34(3):537–43. Available from: http://portalsaudebrasil.com/artigospsb/nutri057.pdf
- Gotshalk LA, Kraemer WJ, Mendonca MAG, Vingren JL, Kenny AM, Spiering BA, et al. Creatine supplementation improves muscular performance in older women. Eur J Appl Physiol. 2008;102(2):223–31.
- Gualano B, Macedo AR, Alves CRR, Roschel H, Benatti FB, Takayama L, et al. Creatine supplementation and resistance training in vulnerable older women: A randomized double-blind placebo-controlled clinical trial. Exp Gerontol [Internet]. 2014;53:7–15. Available from: http://dx.doi.org/10.1016/j.exger.2014.02.003
- Jakobi JM, Rice CL, Curtin S V., Marsh GD. Neuromuscular properties and fatigue in older men following acute creatine supplementation. Eur J Appl Physiol. 2001;84(4):321–8.

- McMorris T, Mielcarz G, Harris RC, Swain JP, Howard A. Creatine supplementation and cognitive performance in elderly individuals. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2007;14(January 2015):517–28.
- Norman K, Stübler D, Baier P, Schütz T, Ocran K, Holm E, et al. Effects of creatine supplementation on nutritional status, muscle function and quality of life in patients with colorectal cancer-A double blind randomised controlled trial. Clin Nutr. 2006;25(4):596– 605.
- Rawson ES, Clarkson PM. Acute creatine supplementation in older men. Int J Sports Med. 2000;21(1):71–5.
- Rawson ES, Wehnert ML, Clarkson PM. Effects of 30 days of creatine ingestion in older men. Eur J Appl Physiol Occup Physiol. 1999;80(2):139–44.
- Roy BD, De Beer J, Harvey D, Tarnopolsky MA. Creatine monohydrate supplementation does not improve functional recovery after total knee arthroplasty. Arch Phys Med Rehabil. 2005;86(7):1293–8.
- Stout JR, Graves BS, Cramer JT, Goldstein ER, Costa PB, Smith AE, et al. Effects of creatine supplementation on the onset of neuromuscular fatigue threshold and muscle strength in elderly men and women (64-86 years). J Nutr Heal Aging. 2007;11(6):459–64.
- Wilkinson TJ, Lemmey AB, Jones JG, Sheikh F, Ahmad YA, Chitale S, et al. Can Creatine Supplementation Improve Body Composition and Objective Physical Function in Rheumatoid Arthritis Patients? A Randomized Controlled Trial. Arthritis Care Res [Internet]. 2016;68(6):729–37. Available from:

http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L6105 31507%5Cnhttp://dx.doi.org/10.1002/acr.22747%5Cnhttp://findit.library.jhu.edu/resolve ?sid=EMBASE&issn=21514658&id=doi:10.1002%2Facr.22747&atitle=Can+Creatine+ Supplementation+Imp

- Wiroth JB, Bermon S, Andreï S, Dalloz E, Hébuterne X, Dolisi C. Effects of oral creatine supplementation on maximal pedalling performance in older adults. Eur J Appl Physiol. 2001;84(6):533–9.
- Villanueva MG, He J, Schroeder ET. Periodized resistance training with and without supplementation improve body composition and performance in older men. Eur J Appl Physiol. 2014;114(5):891–905.
- 45. Collins J. Resistance Training and Co-supplementation with Creatine and Protein in Older Subjects with Frailty. 2015;(July).
- Halpern SH, Douglas MJ. Jadad scale for reporting randomized controlled trials. 2005;237–8.
- 47. Denison HJ, Cooper C, Sayer AA, Robinson SM. Prevention and optimal management

of sarcopenia : a review of combined exercise and nutrition interventions to improve muscle outcomes in older people. 2015;859–69.

48. Devries MC, Phillips SM. Creatine Supplementation during Resistance Training in Older Adults—A Meta-analysis. 2014;(42).

APPENDIX

Database	Full electronic search										
Medline	("creatine"[MeSH Terms] OR "creatine"[All Fields]) AND ("dietary										
	supplements"[MeSH Terms] OR "dietary supplements"[All Fields] OR "food										
	supplements" [All Fields]) AND ("aged" [MeSH Terms] OR "aged" [All Fields]										
	OR "older adults" [All Fields] OR "elderly" [All Fields])										
Cochrane	ID Search										
	#1 MeSH descriptor: [Creatine] explode all trees										
	#2 MeSH descriptor: [Dietary Supplements] explode all trees										
	#3 MeSH descriptor: [Aged] explode all trees										
	#4 MeSH descriptor: [Middle Aged] explode all trees										
	#5 (#1 and #2)										
Embase	#1 'creatine'/exp OR 'creatine' AND ([english]/lim OR [french]/lim OR										
	[portuguese]/lim OR [Spanish]/lim) AND ([middle aged]/lim OR [aged]/lim)										
	AND [humans]/lim										
	# 2 'diet supplementation'										
	#3 #1 AND #2										

S1 – Full electronic search strategy of Medline, Cochrane and Embase databases.

	Randomization (0-2)	Blinding (0-2)	Withdrawals and drop outs (0-1)	Total Score
Aguiar, 2012	1	2	1	4
Alves, 2013	2	2	1	5
Bender, 2008	1	1	1	3
Brose, 2003	1	2	1	4
Candow, 2008	1	2	1	4
Cañete, 2006	1	2	1	4
Chilibeck, 2005	1	2	1	4
Chrusch, 2001	1	2	1	4
Collins, 2015	1	1	1	3
Cooke, 2014	1	2	1	4
Deacon, 2008	2	2	1	5
Eijnde, 2003	1	1	1	3
Faager, 2006	1	2	1	4
Fuld, 2005	1	2	1	4
Gotshalk, 2002	1	2	1	4
Gotshalk, 2008	1	2	0	3
Gualano, 2014	2	2	1	5
Hass, 2007	1	2	0	3
Jakobi, 2001	1	2	0	3
McMorris, 2007	0	1	0	1
Norman, 2006	1	2	1	4
Rawson, 1999	1	2	0	3
Rawson, 2000	1	2	1	4
Roy, 2005	2	2	0	4
Stout, 2007	1	2	0	3
Villanueva, 2014	1	0	1	2
Wilkinson, 2016	2	2	1	5
Wiroth, 2001	1	1	0	2

S2 – Jadad Scale : review authors' judgements about each risk of bias.

Study

1) Body	/ mass											
Study	Mean age (SD)	Sample size	% males	Population	Duration (weeks)	Intervention	Creatine (dose per day)	Proteins (dose per day)	Placebo (dose per day)	Exercise type, Duration (sessions/week)	Effect on Cr group	Conclusions
Aguiar, 2012	64.9 (5)	PL=9 PL=9	%0	Older women	24	Creatine + Training	CrM+dextrose= 5g+2g/d	1.	Dextrose=7g/d	Resistance, 3 s/w for the last 12w	÷	Both CR and PL groups increased body mass with no significant differences within and between groups.
Brose, 2003	68.7 (4.8)	CR=14 PL=14	CR=57% PL=50%	Older adults	14	Creatine + Training	CrM+dextrose=5g+2g /d	а	Dextrose=7g/d	Resistance, 3 s/w	↑ Pre: 84.1(14)k g Post: 85.5(13.5) kg	CR group significantly (p<0.05) increased body mass while PL group decreased. No significant differences between groups.
Cooke, 2014	61.4 (5.0)	CR= 10 PL=10	100%	Older men	12	Creatine + Training	CrM+CHO= 20 g + 5 g /d for 7 days followed by 0.1 g//g/d of CrM + 5 g/d of glucose on training days	3	CHO= 20 g of glucose only for 7 days followed by 5 g of glucose on training days	Resistance, 3s/w	† Pre: 88.2(12.4) kg Post: 89.9(11.8) kg	Both CR and PL groups significantly (p 0<0.05) increased body mass. Increase on CR group was significantly (p<0.05) greater than PL group.
, 2008	68.2 (8.2)	CR=38 PL=42	CR=50% PL=74%	COPD	2	Creatine + Training	CrM=22g/d for 5d followed by 3.76g/d during pulmonary rehabilitation	н	Lactose=24g/d for 5d followed by 4g/d during pulmonary rehabilitation	Pulmonary rehabilitation, 21 s/w	÷	Both CR and PL groups increased body mass with no significant differences within or between groups
Eijnde, 2003	65.3 (1.3)	CR=15 PL=21	100%	Older Men	48	Creatine + Training	CrM=5g/d	1.	r.	Endurance + Resistance, 2-3 s/w	÷	CR group increased body mass while PL group decreased. No significant differences within or between groups.
Faager, 2006	66.0 (6.0)	CR=13 PL=10	CR=46% PL=40%	сорр	00	Creatine + Training	CR?=0.3g/kg/d during 7d followed by 0.07g/kg/d during the remaining 7 weeks	t	Glucose= ?	Pulmonary Rehabilitation, 2 s/w	÷	Both CR and PL groups increased body mass with no significant differences within or between groups
Fuld, 2005	61.7 (8.0)	CR=14 PL=11	r.,	COPD	12	Creatine + Training	CrM + glucose= 5g+35g 3x/d for 14 days followed by 5g+35 1x/d for 10weeks	1	Glucose polymer= 40.7g 3x/d for 14 days followed by 40.7g 1x/d for 10 weeks	Pulmonary Rehabilitation, 2s/w	÷	Both CR and PL groups increased body mass with no significant differences within or between groups.
Gotshal k, 2002	65.4 (1.5)	CR=10 PL=8	100%	Older Men	H	Creatine	CrM= 0.3G/KG	§1	Celulose powder=0.3 g/kg	1	↑ Pre: 84.8(13.0 2)kg Post: 86.45(17. 11)kg	CR group significantly (p<0.05) increased body mass while PL group decreased. No significant differences between

S3- Details regarding body composition.

Both CR and PL groups increased body mass with no significant differences within or between groups	CR group significantly (p<0.05) increased body mass while PL group had no changes. No significant differences between groups.	Both CR and PL groups increased body mass with no significant differences within or between groups	Both CR and PL groups increased body mass with no significant differences within or between groups.	CR group significantly (p<0.05) increased body mass while PL group had no changes. No significant differences between groups.	Both CR and PL groups decreased body mass with no significant differences within or between groups.	CR group increased body mass while PL group decreased. No significant differences between groups.	Both CR and PL groups increased body mass with no significant differences within or between groups	All groups increased body mass with no significant differences within or between groups.
÷	↑ Pre: 83(4)kg Post: 84(4)kg	÷	÷	↑ Pre: 86.2(3.4)k g Post: 86.7(3.4)k g	<i>→</i>	÷	÷	÷
a	E	£	a -	а	a	15	e.	1
owder=?	rin= 5g/d	20g/d for eek y 5g/d	25g/d for ed by 20g	volume ce	14g on e surgery or 30d ery	nt end=?	rink	rose=
Celulose p	Maltodext	Cellulose= the first w followed b for 7w	Dextrose= 10d follow dextrose	Equivalent of look-alii sucrose=?	Dextrose= 10d before and 7g/d f after surge	Flavored effervesce powder bl	Flavored d powder	Casein suc 30g+15g/o
1	Ĩ.	1	1	i.	0	l.	C.	1
CrM=0.3 g/kg/d	CrM + Maltodextrin= 5g/d	CrM= 20g/d for the first week followed by 5/d for 7w	CrM + dextrose= 20g+28g/d during 10 days, followed by 4g+6.8g	CrM+sucrose= 20g+4g/d	CrM+dextrose= 10g+8g d on the 10d before surgery and 5g+4g/d for 30d after surgery	Di-Creatine- Citrate=20g/d during for the first week followed by 10g/d	CrM= 20g/d for the initial 5d followed by 3g/d	CrM+sucrose=15g+ 30g/d
Creatine	Creatine	Creatine	Creatine	Creatine	Creatine	Creatine	Creatine	Creatine
	₽	60	4	₽	9	2	12	₽
Older Women	Older Men	Colorectal Cancer	Older Men	Older Men	Total joint arthroplasty	Older subjects	Rheumatoid Arthritis	Older men
%0	100%	CR=62,5 % PL=66,7 %	100%	100%	CR=50% PL=42%	47%	CR=23% PL= 30%	100%
CR=15 PL=12	CR=7 PL=5	CR=16 PL=15	CR=10 PL=10	CR=9 PL=8	CR=18 PL=19	CR=? PL=?	CR=15 PL=20	CR=14 PL=14
63.3 (1.2)	72.0 (2.0)	65.1 (12.6)	66.7 (1.9)	65.0 (2.1)	63.3 (10.2)	74.5 (6.4)	63.0 (10.0)	69.4(?)
Gotshal k, 2008	Jakobi, 2001	Norma n, 2006	Rawson , 1999	Rawson , 2000	Roy, 2005	Stout, 2007	Wilkins on, 2016	Wiroth 2001

groups.

	Conclusions	oth CR and PL groups reased body mass. The crease was significant 0.01 on CR group. No ignificant differences between groups	h CR+PR and PR group lificantly (p<0.05) eased FFM without lificant differences ween groups.	h groups significantly eased FFM. CR group h p<0.01 and PL with .01. No significant erences between ups.	group significantly 0.01) increased FFM le PL group decreased The differences ween groups are ificant (p<0.05).	group inficantly(P<0.05) eased FMM while PL up had no changes. No inficant differences ween groups.	h CR and PL groups eased FFM with no ifficant differences vin or between groups.	group decreased FFM le PL group increased. significant differences
	Effect on Cr group	↑ Pre: B 35.1(2.3 inc)kg in Post: (p ^s)kg	↑ Pre: Boti 44.1(7.6 sign)kg incr Post: sign 44.5(9.4 beth)kg	↑ Boti 0.9(1.6) incr kg with p≤0 diffi grou	↑ 2.0 CR ((1.9) kg (p<6 (white the the the the the the the the the t	↑ ↑ ₽re: CR 6 61.10(6. sign 58)kg incr 58)kg gro 90st: gro 63.32(7. sign 80)kg bet	A Both incr sign with	+ N whi
	Exercise type, Duration (sessions/week)	Resistance, 3 sessions/w for the last 12w	Resistance, 2s/w	Pulmonary rehabilitation, 21 s/7w	Pulmonary Rehabilitation, 2s/w	1	Ŀ	1
	Placebo (dose per day)	Dextrose=7g/d	N -	Lactose=24g/d for 5d followed by 4g/d during pulmonary rehabilitation	Glucose polymer- 40.7g 3x/d for 14 days followed by 40.7g 1x/d for 10 weeks	Cellulose powder=0.3 g/kg	Celulose powder=??	Dextrose= 25g/d for 10d followed by 20g dextrose
	Proteins (dose per day)	1	p.,	1	1	1	ĩ	1
	Creatine (dose per day)	CrM+dextrose= 5g+2g/d	P••	CrM=22g/d for 5d followed by 3.76g/d during pulmonary rehabilitation	CrM + glucose= 5g+35g 3x/d for 14 days followed by 5g+35 1x/d for 10weeks	CrM= 0.3G/KG	CrM=0.3 g/kg/d	CrM + dextrose= 20g+28g/d during 10 days, followed by
	Intervention	Creatine + Training	Creatine + Protein + Training	Creatine + Training	Creatine + Training	Creatine	Creatine	Creatine
	Duration (weeks)	24	14	~	12	÷	F	4
	Population	Older women	Older adults	сорр	сорр	Older Men	Older Women	Older Men
	% males	%0	p.,	CR=50% PL=74%	r	100%	%0	100%
ISS (FFM)	Sample size	CR=9 PL=9	9 PR=7	CR=38 PL=42	CR=14 PL=11	PL=8	CR=15 PL=12	CR=10 PL=10
Free Ma	Mean age (SD)	64.9(5)	70.33 (?)	68.2 (8.2)	61.7 (8.0)	65.4 (1.5)	63.3 (1.2)	66.7 (1.9)
2) Fat I	Study	Aguiar, 2012	Collins, 2016	, 2008	Fuld, 2005	Gotshal k, 2002	Gotshal k, 2008	Rawson 1999

a l	63.3	CR=15	%0	Older	1	Creatine	CrM=0.3 g/kg/d	ĩ	Celulose powder=??	a		between groups. Both CR and PL groups
	(1.2)	PL=12	, est	Women	ž		and should be a				a 4	increased FFM with no significant differences within or between groups.
	1.00 (4.8)	CK=I5 PL=15 CR+TR= 15 PL+TR=1 5	6	vumerable Older Women	47	Creatine	crm=zug.a ror 5 days followed by single daily dose of 5g	1	Dextrose=20g(day for 5 days followed by single daily doses of 5g	kesistance, z s/w	÷	ck group increased FFM while PL decreased. No significant differences within or between groups.
	66.7 (1.9)	CR=10 PL=10	100%	Older Men	4	Creatine	CrM + dextrose= 20g+28g/d during 10 days, followed by 4g+6.8g	1	Dextrose= 25g/d for 10d followed by 20g dextrose	3	÷	CR group decreased FFM while PL group increased. No significant differences within or between groups
	65.0 (2.1)	CR=9 PL=8	100%	Older Men	₽	Creatine	CrM+sucrose= 20g+4g/d	ī	Equivalent volume of look-alike sucrose=?	E	÷	CR group increased FFM while PL group decreased. No significant differences within or between groups.
>	63.3 (10.2)	CR=18 PL=19	CR=50% PL=42%	Total joint arthroplasty	ou	Creatine	CrM+dextrose= 10g+8g d on the 10d before surgery and 5g+4g/d for 30d after surgery	ĩ	Dextrose= 14g on 10d before surgery and 7g/d for 30d after surgery	£	÷	Both CR and PL groups increased FFM with no significant differences within or between groups
	Mean age (SD)	Sample size	% males	Population	Duration (weeks)	Intervention	Creatine (dose per day)	Proteins (dose per day)	Placebo (dose per day)	Exercise type, Duration (sessions/week)	Effect on Cr group	Conclusions
	64.9 (5)	CR=9 PL=9	%0	Older women	24	Creatine + Training	CrM+dextrose= 5g+2g/d	1	Dextrose=7g/d	Resistance, 3 sessions/w for the last 12w	÷	CR group decreased body fat while PL group increased. No significant differences inside or between groups
	68.7 (4.8)	CR=14 PL=14	CR=57% PL=50%	Older adults	14	Creatine + Training	CrM+dextrose=5g+2g /d	1	Dextrose=7g/d	Resistance, 3 s/w	÷	Both CR and PL groups decreased Body Fat with no significant differences within or between groups.
	70.4 (1.6)	CR=16 PL=14	100%	Older Men	12	Crreatine + Training	Cr+sucrose=0.3 g/kg/d for the first 5d followed by 0.07 g/kg/d	1	Sucrose Fluor Mixture=0.3g/d for the first 5d followed by 0.07g/d	Resistance , 3s/w	↓ Pre: 88.0(3.6) % Post: 91.0(3.8)	Both CR and PL groups significantly (p<0.05) decreased body fat without significant differences between

CR group decreased body fat while PL group had no changes. No significant differences within or between groups.	Both CR and PL groups significantly (p<0.05) decreased body fat without significant differences between groups.	Both CR and PL groups decreased body fat without significant differences within or between groups.	Both CR and PL groups decreased body fat without significant differences within or between groups.	CR group decreased body fat while PL group increased. No significant differences within or between groups	CR group decreased body fat while PL group increased. No significant differences within or between groups	Both CR and PL groups decreased body fat without significant differences within or between groups.	Both CR+PR and PR groups decreased body fat without significant differences inside and between groups.
÷	 ↓ Pre: 27.2(1.2))% Post: 26.2(1.2))% 	÷	÷	÷	÷	÷	÷
Resistance, 3s/w	Endurance + Resistance, 2-3 s/w	9	1.	L.	Ŀ	9.	Resistance, 3 s/w
CHO= 20 g of glucose only for 7 days followed by 5 g of glucose on training days	P	Cellulose powder=0.3 g/kg	Cellulose powder=?	Dextrose= 25g/d for 10d followed by 20g dextrose	Equivalent volume of look-alike sucrose=?	Dextrose= 14g on 10d before surgery and 7g/d for 30d after surgery	3
3	1)	t.		i.	ĩ	Liquid protein=3 5g/d
CrM+CHO= 20 g+5 g /d for 7 days followed by 0.1 g/kg/d of crM + 5 g/d of glucose on training days	CrM=5g/d	CrM= 0.3G/KG	CrM=0.3 g/kg/d	CrM + dextrose= 20g+28g/d during 10 days, followed by 4g+6.8g	CrM+sucrose= 20g+4g/d	CrM+dextrose= 10g+8g d on the 10d before surgery and 5g+4g/d for 30d after surgery	CrM= 0.3g/kg/d for 5d followed by 0.07g/kg/d
Creatine + Training	Creatine + Training	Creatine	Creatine	Creatine	Creatine	Creatine	Creatine + Protein + Training
12	84	Ŧ	1	4	₽	9	12
Older men	Older Men	Older Men	Older Women	Older Men	Older Men	Total joint arthroplasty	Older Men
100%	100%	100%	%0	100%	100%	CR=50% PL=42%	100%
CR= 10 PL=10	CR=15 PL=21	CR=10 PL=8	CR=15 PL=12	p.,	CR=9 PL=8	CR=18 PL=19	PR+TR= 7 TR=7 C=8
61.4 (5.0)	65.3 (1.3)	65.4 (1.5)	63.3 (1.2)	66.7 (1.9)	65.0 (2.1)	63.3 (10.2)	68.1 (6.1)
Cooke, 2014	Eijnde, 2003	Gotshal k, 2002	Gotshal k, 2008	Rawson 1999	Rawson 2000	Roy, 2005	Villanu eva, 2014

groups.

Both CR and PL groups increased body fat without significant differences within or between groups.		Conclusions	CR group increased BMC while PL decreased. No significant differences within or between groups.	Both CR and PL groups increased BMC without significant differences within or between groups.	Both CR and PL groups decreased BMC without significant differences within or between groups.	Conclusions	Both CR and PL groups significantly (p<0.05) increased BMD without significant differences between groups.	Both CR+PR and PR groups increased BMD without significant differences within or between groups	Both CR and PL groups presented no changes in BMD.
\rightarrow		Effect on Cr group	÷	÷	÷	Effect on Cr group	↑ Pre: 0.980(0. 088)g/c m2 Post:0.9 85(0.08 8)g/cm2	÷	0
13		Exercise type, Duration (sessions/week)	Resistance, 3 s/w	Resistance, 2s/w	Resistance, 2 s/w	Exercise type, Duration (sessions/week)	Resistance, 3 s/w	Resistance, 2s/w	Resistance, 2 s/w
Flavored drink powder=?		Placebo (dose per day)	Sucrose Fluor Mixture=0.3g/d 1st 5d followed by 0.07g/d	Pu.	Dextrose=20g/day for 5 days followed by single daily doses of 5g	Placebo (dose per day)	Sucrose Fluor Mixture=0.3g/d 1st 5d followed by 0.07g/d	r	Dextrose=20g/day for 5 days followed by single daily doses of 5g
L.		Proteins (dose per day)	1	P	r.	Proteins (dose)	1	p.,	1
CrM= 20g/d for the initial 5d followed by 3g/d		Creatine (dose per day)	Cr=0.3g/d 1st 5d followed by 0.07g/d	P-1	CrM=20g/d for 5 days followed by single daily dose of 5g	Creatine (dose per day)	Cr=0.3g/d 1st 5d followed by 0.07g/d	P••	CrM=20g/d for 5 days followed by single daily dose of 5g
Creatine		Intervention	Creatine + Training	Creatine + Protein + Training	Creatine	Intervention	Creatine + Training	Creatine + Protein + Training	Creatine
12		Duration (weeks)	12	14	24	Duration (weeks)	12	14	24
Rheumatoid Arthritis		Population	Older Men	Older adults	Vulnerable Older Women	Population	Older Men	Older adults	Vulnerable Older Women
CR=23% PL= 30%		% males	100%	r	%0	% males	100%	P	%0
CR=15 PL=20	Content	Sample size	CR=16 PL=13	CR+PR= 9 PR=7	CR=15 PL=15 CR+TR= 15 PL+TR=1 5	l Density Sample size	CR=16 PL=13	CR+PR= 9 PR=7	CR=15 PL=15 CR+TR= 15
63.0 (10.0)	Minera	Mean age (SD)	70 (6.6)	70.33 (?)	66.1 (4.8)	Minera Mean age (SD)	70 (6.6)	70.33 (?)	66.1 (4.8)
Wilkins on 2016	4) Bone	Study	Chilibec k, 2015	Collins, 2016	Gualan o, 2014	5) Bone Study	Chilibec K, 2015	Collins, 2016	Gualan o, 2014

PL+TR=1

6) Mus Study	cle fibers Mean age (SD)	Sample size	% males	Population	Duration (weeks)	Intervention	Creatine (dose per day)	Proteins (dose per day)	Placebo (dose per day)	Exercise type, Duration (sessions/week)	Effect on Cr group	Conclusions
Brose 2003	68.7 (4.8)	CR=14 PL=14	CR=57% PL=50%	Older adults	14	Creatine + Training	CrM+dextrose=5g+2g /d	1	Dextrose=7g/d	Resistance, 3 s/w	÷	Both CR and PL groups increased muscle fibers with no significant differences within or between groups.
Cooke, 2014	61.4 (5.0)	CR= 10 PL=10	100%	Older men	12	Creatine + Training	CrM+CHO= 20 g + 5 g /d for 7 days followed by 0.1 g/kg/d of CrM + 5 g/d of glucose on training days	1	CHO= 20 g of glucose only for 7 days followed by 5 g of glucose on training days	Resistance, 3s/w	н	Both CR and PL groups increased muscle fibers. CR group had a significant increase in muscle fibers <u>type II.</u> No significant differences between groups.
7) Mus Study	cle creati Mean age (SD)	ine Sample size	% males	Population	Duration (weeks)	Intervention	Creatine (dose per day)	Proteins (dose per day)	Placebo (dose per day)	Exercise type, Duration (sessions/week)	Effect on Cr group	Conclusions
Brose 2003	68.7 (4.8)	PL=14	PL=50%	Older adults	14	Creatine + Training	/d /d	1	Dextrose=7g/d	Resistance, 3 s/w	↑ Pre: 116.8(1 4.5)mm olkg- 1dm Post: 159.3(2 3.9)mm olkg- 1dm	CR group significantly(P-0.05) increased muscle creatine while PL decreased. No significant differences between groups.
Eijnde, 2003	65.3 (1.3)	CR=15 PL=21	100%	Older Men	88	Creatine + Training	CrM=5g/d	а	Deep	Endurance + Resistance, 2-3 s/w		CR group increased muscle creatine while PL group decreased. No significant differences within or between groups.

8) Musc	le phos	phocreati	ne									
Study	Mean age (SD)	Sample size	% males	Population	Duration (weeks)	Intervention	Creatine (dose per day)	Proteins (dose per day)	Placebo (dose per day)	Exercise type, Duration (sessions/week)	Effect on Cr group	Conclusions
Brose 2003	68.7 (4.8)	CR=14 PL=14	PL=50%	Older adults	14	Creatine + Training	/d	1	Dextrose=7g/d	Resistance, 3 s/w	↑ Pre: 67.4(19. 7)mmol kg-1dm Post: 88.0(20. 5)mmol kg-1dm	Cr group significantly (p<0.05) increased muscle phosphocreatine while PL decreased. No significant differences between groups.
Ejinde, 2003	65.3 (1.3)	CR=15 PL=21	100%	Older Men	8	Creatine + Training	CrM=5g/d	1	Pro-	Endurance + Resistance, 2-3 s/w	A Pre: 102.3(4. /kgdryw /kgdryw 114.2(5. 0)mmol /kgdryw t	CR group significantly(P<0.05) increased muscle phosphocreatine while PL decreased. No significant differences between groups.

hronic Obstructive Pulmonary Disease
D, CI
IOPI
rM-carbohydrate; C
Ū,
CHC
Ionohydrate; (
Creatine N
CrM,
protein; (
PR,
placebo;
PL,
creatine;
CR.

1) Prote	sins											
Study	Mean age (SD)	Sample size	% males	Population	Duration (weeks)	Intervention	Creatine (dose per day)	Proteins (dose)	Placebo (dose per day)	Exercise type, Duration (sessions/week)	Effect on Cr group	Conclusions
Alves, 2013	66.9 (4.9)	CR=13 PL=12 CR+TR=12 PL+TR=10	%0	Older women	24	Creatine + Training	CrM=20g/d for 5d followed by 5g/d	1	Dextrose= 20g/d for 5d followed by 5g/d	Resistance, 25/w	÷	Both CR and PL groups increased protein intake without significant differences within or between groups.
cando w, 2008	65.6 (2.7)	CrP=10 CR=12 PL=12	100%	Older Men	10	Creatine + Protein + Training	CrM= 0.1 g/kg/D	Protein?= 0.3 g/kg/d	Chocolate and Cherry-flavored sucrose powder =1.2 g/kg/d	Resistance 3s/w	÷	Both CR and PL groups increased protein intake while CR+PR group decreased. No significant differences within or between groups.
collins, 2016	70.33 (?)	CR+PR=9 PR=7	c	Older adults	14	Creatine + Protein + Training	Pr-	p	P	Resistance, 2s/w	÷	Both CR+PR and PR groups increased protein intake without significant differences within or between groups.
Cooke, 2014	61.4 (5.0)	CR= 10 PL=10	100%	Older men	12	Creatine + Training	CrM+CHO= 20 g + 5 g /d for 7 days followed by 0.1 g/kg/d of crM + 5 g/d of glucose on training days	ч	CHO= 20 g of glucose only for 7 days followed by 5 g of glucose on training days	Resistance, 3s/w	÷	CR group decreased protein intake while PL group increased. No significant differences within or between groups
Gualan o, 2014	66.1 (4.8)	CR=15 PL=15 CR+TR=15 PL+TR=15	%0	Vulnerable Older Women	24	Creatine	CrM=20g/d for 5 days followed by single daily dose of 5g	1	Dextrose=20g/day for 5 days followed by single daily doses of 5g	Resistance, 2 s/w	÷	CR group increased protein intake while PL group decreased. No significant differences within or between groups
Rawson 1999	66.7 (1.9)	CR=10 PL=10	100%	Older Men	4	Creatine	CrM + dextrose= 20g+28g/d during 10 days, followed by 4g+6.8g/d	9	Dextrose= 25g/d for 10d followed by 20g dextrose	a	÷	Both CR and PL groups decreased protein intake without significant differences within or between groups.

S4- Details regarding nutrients intake.

nclusions	d PL groups carbohydrates iout significant within or oups.	(CR, CR+PR, PL) carbohydrates significant within or oups	up decreased stes intake creased. No differences etween groups	ecreased ste Intake while icreased. No differences etween groups	ecreased ate Intake while Icreased. No differences etween groups	ncreased ste Intake while ecreased. No differences etween groups.
ē	Both CR an increased of Intake with differences	All groups decreased Intake. No differences between g	CR+PR grou carbohydra while PR in significant within or b	CR group d carbohydra PL group ir significant within or b	CR group d carbohydra PL group ir significant within or b	CR group ir carbohydra PL group d significant within or b
Effect on Cr group	÷	÷	÷	÷	÷	÷
Exercise type, Duration (sessions/week)	Resistance, 2s/w	Resistance 3s/w	Resistance, 2s/w	Resistance, 3s/w	Resistance, 2 s/w	1
Placebo (dose per day)	Dextrose= 20g/d for 5d followed by 5g/d	Chocolate and Cherry-flavored sucrose powder =1.2 g/kg	0	CHO= 20 g of glucose only for 7 days followed by 5 g of glucose on training days	Dextrose=20g/day for 5 days followed by single daily doses of 5g	Dextrose= 25g/d for 10d followed by 20g dextrose
Proteins (dose per day)	1	Protein?= 0.3 g/kg/d	r	3	i.	ï
Creatine (dose per day)	CrM=20g/d for 5d followed by 5g/d	CrM= 0.1 g/kg/D	P er	CrM+CHO= 20 g + 5 g /d for 7 days followed by 0.1 g/kg/d of crM + 5 g/d of glucose on training days	CrM=20g/d for 5 days followed by single daily dose of 5g	CrM + dextrose= 20g+28g/d during 10 days, followed by 4g+6.8g
Intervention	Creatine + Training	Creatine + Protein + Training	Creatine + Protein + Training	Creatine + Training	Creatine	Creatine
Duration (weeks)	24	10	14	12	24	4
Population	Older women	Older Men	Older adults	Older men	Vulnerable Older Women	Older Men
% males	%0	100%	۳.	100%	%0	100%
.es Sample size	CR=13 PL=12 CR+TR=12 PL+TR=10	CrP=10 CR=12 PL=12	CR+PR=9 PR=7	CR= 10 PL=10	CR=15 PL=15 CR+TR=15 PL+TR=15	CR=10 PL=10
ohydrat Mean age (SD)	66.9 (4.9)	65.6 (2.7)	70.33 (?)	61.4 (5.0)	66.1 (4.8)	66.7 (1.9)
2) Carb Study	Alves, 2013	cando w 2008	Collins, 2016	Cooke, 2014	Gualan o, 2014	Rawson 1999

3) Fat												
Study	Mean age (SD)	Sample size	% males	Population	Duration (weeks)	Intervention	Creatine (dose per day)	Proteins (dose per day)	Placebo (dose per day)	Exercise type, Duration (sessions/week)	Effect on Cr group	Conclusions
Alves, 2013	66.9 (4.9)	CR=13 PL=12 CR+TR= 12 PL+TR=1 0	%0	Older women	24	Creatine + Training	CrM=20g/d for 5d followed by 5g/d	ı	Dextrose= 20g/d for 5d followed by 5g/d	Resistance, 2s/w	÷	CR group decreased Fat Intake while PL group increased. No significant differences within or between groups
Cando w 2008	65.6 (2.7)	CrP=10 CR=12 PL=12	100%	Older Men	10	Creatine + Protein + Training	CrM= 0.1 g/kg/D	Protein?= 0.3 g/kg/d	Chocolate and Cherry-flavored sucrose powder =1.2 g/kg	Resistance 3s/w	÷	Both CR and PL groups increased fat intake while CR+PR group decreased. No significant differences within or between groups.
Collins, 2016	70.33 (?)	CR+PR= 9 PR=7	P	Older adults	14	Creatine + Protein + Training	6-	p.,	6	Resistance, 2s/w	÷	CR+PR group decrease fat intake while PR group increased. No significant differences within or between groups
Cooke, 2014	61.4 (5.0)	CR= 10 PL=10	100%	Older men	12	Creatine + Training	CrM+CHO= 20 g + 5 g /d for 7 days followed by 0.1 g/kg/d of crM + 5 g/d of glucose on training days	ą.	CHO= 20 g of glucose only for 7 days followed by 5 g of glucose on training days	Resistance, 3s/w	÷	CR group decreased fat intake while PL group increased. No significant differences within or between groups.
Gualan o, 2014	66.1 (4.8)	CR=15 PL=15 CR+TR= 15 PL+TR=1 5	%0	Vulnerable Older Women	24	Creatine	CrM=20g/d for 5 days followed by single daily dose of 5g	1	Dextrose=20g/day for 5 days followed by single daily doses of 5g	Resistance, 2 s/w	÷	CR group increased fat intake while PL group decreased. No significant differences within or between groups.
Rawson 1999	66.7 (1.9)	CR=10 PL=10	100%	Older Men	4	Creatine	CrM + dextrose= 20g+28g/d during 10 days, followed by 4g+6.8g	t.	Dextrose= 25g/d for 10d followed by 20g dextrose	Ū.	÷	CR group decreased fat intake while PL group increased. No significant differences within or between groups.

	a 010.	Sample size CR=13 PL=12 CR+TR=	% males 0%	Population Older women	Duration (weeks) 24	Intervention Creatine + Training	Creatine (dose per day) CrM=20g/d for 5d followed by 5g/d	Proteins (dose per day) -	Placebo (dose per day) Dextrose= 20g/d for 5d followed by 5g/d	Exercise type, Duration (sessions/week) Resistance, 2s/w	Effect on Cr group	Conclusions
	CR+PR= 7) PR=7	(r.,	1.21	Older adults	14	Creatine + Protein + Training	P	c .	P	Resistance, 2s/w	\rightarrow	
Older adults 14 Creatine + ? ? ? Resistance, Protein + 23/w Training	CR= 10 1 2L=10		%00	Older men	12	Creatine + Training	CrM+CHO= 20 g + 5 g /d for 7 days followed by 0.1 g/kg/d of crM + 5 g/d of glucose on training days	1	CHO= 20 g of glucose only for 7 days followed by 5 g of glucose on training days	Resistance, 3s/w	\rightarrow	
Older adults 14 Creatine + Protein + Training ? ? ? Resistance, 25/w 00% Older men 12 Creatine + (d for 7 days followed by 0.1 g/kg/d of crM + 5 g/d of glucose on training days - CHO= 20 g of glucose Resistance, 25/w	CR=15 0 2(=15 2R+TR= 2R+TR= 15 15	0	*	Vulnerable Older Women	24	Creatine	CrM=20g/d for 5 days followed by single daily dose of 5g	0	Dextrose=20g/day for 5 days followed by single daily doses of 5g	Resistance, 2 s/w	÷	
Older adults 14 Creatine + Protein + Training ? ? ? Resistance, 2s/w 00% Older men 12 Creatine + Training /d for 7 days followed by 0.1 g/kg/d of crM + 5 g/d of glucose on training days - CHO=20g of glucose followed by 5 g of glucose on training 3s/w % Vulnerable 24 Creatine + by 0.1 g/kg/d of crM + 5 g/d of glucose on training days - CHO=20g of glucose followed by 5 g of glucose on training Si /d for 7 days followed by 5 g of glucose on training % Vulnerable 24 Creatine + followed by single - Dextrose-20g/day for single daily dose of 5 g -	2K=10 1	-	%00	Older Men	4	Creatine	CrM + dextrose= 20g+28g/d during 10 days, followed by 4g+6.8g	i	Dextrose= 25g/d for 10d followed by 20g dextrose	u	\rightarrow	

CR, creatine; PL, placebo; PR, protein; CrM, Creatine Monohydrate; CHO, CrM-carbohydrate; COPD, Chronic Obstructive Pulmonary Disease

1RM Be	anch Pres	22										
Study	Mean age (SD)	Sample size	% males	Population	Duration (weeks)	Intervention	Creatine (dose per day)	Proteins (dose per day)	Placebo (dose per day)	Exercise type, Duration (sessions/week)	Effect on Cr group	Conclusions
Aguiar 2012	64.9 (5)	CR=9 PL=9	%0	older women	24	Creatine + Training	CrM+dextrose= 5g+2g/d	ĩ	Dextrose=7g/d	Resistance, 3 sessions/w for the last 12w	↑14.3(6 .7) %	Both groups increased 1RM Bench Press. The increased was significant (p<0.05) in Cr group. No significant differences between groups.
Gotshal k, 2002	65.4 (1.5)	CR=10 PL=8	100%	Older Men	÷	Creatine	CrM= 0.3G/KG	ī	Celulose powder=0.3 g/kg	i	÷	Both groups increased 1RM Bench Press. The increased was significant (p<0.05) in CR group. No significant differences between groups.
Gotshal k, 2008	63.3 (1.2)	CR=15 PL=12	%0	Older Women	1	Creatine	CrM=0.3 g/kg/d	1	Celulose powder=??	1	÷	Both groups increased 1RM Bench Press. No significant differences within or between groups.
Gualan o, 2014	66.1 (4.8)	CR=15 PL=15 CR+TR= 15 PL+TR=1 5	%0	Vulnerable Older Women	24	Creatine	CrM=20g/d for 5 days followed by single daily dose of 5g	ı	Dextrose=20g/da y for 5 days followed by single daily doses of 5g	Resistance, 2 s/w	÷	CR group increased 1RM Bench Press while PL group decreased. No significant differences within or between groups
Villanu eva, 2014	68.1 (6.1)	PR+TR= 7 TR=7 C=8	100%	Older Men	12	Creatine + Protein + Training	CrM= 0.3g/kg/d for 5d followed by 0.07g/kg/d	Liquid protein=3 5g/d	1	Resistance, 3 s/w	÷	Both CR+PR and PL groups increased 1RM Bench Press. No significant differences within or between groups.
1RM Le Study	g Press Mean age (SD)	Sample size	% males	Population	Duration (weeks)	Intervention	Creatine (dose per day)	Proteins (dose per day)	Placebo (dose per day)	Exercise type, Duration (sessions/week)	Effect on Cr group	Conclusions
Alves, 2013	66.9 (4.9)	CR=13 PL=12 CR+TR= 12 PL+TR=1 0	%0	Older women	24	Creatine + Training	CrM=20g/d for 5d followed by 5g/d	i.	Dextrose= 20g/d for 5d followed by 5g/d	Resistance, 2s/w	÷	Cr group increased 1RM Bench Press while PL group decreased. No significant differences within or between groups
Brose 2003	68.7(4 .8)	CR=14 PL=14	CR=57% PL=50%	Older adults	14	Creatine + Training	CrM+dextrose=5g +2g/d	à	Dextrose=7g/d	Resistance, 3 s/w	÷	Both groups increased 1RM Leg Press. No significant differences within or between groups.

S5- Details regarding dynamic and isometric

otshal 63.3(1 CR- 2008 .2) PL=	ualan 66.1 CR: .2014 (4.8) PL= CR- 15 PL+ FL+ 5	llanu 68.1(6 PR+ ra, .1) 7.1) 114 C=£	RM Knee Extensio tudy Mean Sar	age s (SD)	guiar, 64.9(5 CR: 312) PL=	rose 68.7(4 CR= . Et al . 8) PL= 103	otshal 65.4(1 CR- 2002 .5) PL=
a15 0%	-15 0% -15 -1R= -1R=1	+TR= 100% R=7	n nple %ma	ize	60 60	=14 CR=5 :14 PL=5(=10 100% 8
Older Women	Vulnerable Older Women	s Older Men	ales Population		Older women	7% Older adults 0%	s Older Men
-	24	12	Duration	(weeks)	24	14	T
Creatine	Creatine	Creatine + Protein + Training	Intervention		Creatine + Training	Creatine + Training	Creatine
CrM=0.3 g/kg/d	CrM=20g/d for 5 days followed by single daily dose of 5g	CrM= 0.3g/kg/d for 5d followed by 0.07g/kg/d	Creatine	(dose per day)	CrM+dextrose= 5g+2g/d	CrM+dextrose=5g +2g/d	CrM= 0.3G/KG
t	3	Liquid protein=3 5g/d	Proteins	(dose per day)	a.	a	1
Celulose powder=??	Dextrose=20g/da y for 5 days followed by single daily doses of 5g	3	Placebo	(dose per day)	Dextrose=7g/d	Dextrose=7g/d	Celulose powder=0.3 g/kg
1:	Resistance, 2 s/w	Resistance, 3 s/w	Exercise type,	Duration (sessions/week)	Resistance, 3 sessions/w for the last 12w	Resistance, 3 s/w	1.
÷	÷	÷	Effect	on Cr group	↑ 8.6(2.7) %	÷	÷.
Both groups increased 1RM Leg Press. No significant differences within or between groups.	Both groups increased 1RM Leg Press. No significant differences within or between groups.	Both CR+PR and PL groups increased 1RM Leg Press. No significant differences between groups.	Conclusions		Both groups increased 1RM Knee extension. The increased was significant (p<0.05) in CR group. No significant differences between groups.	Both groups increased 1RM Knee extension. No significant differences within or between groups.	Both groups increased 1RM Knee extension. The increased was significant (p<0.05) in CR group. No significant differences betweet

Conclusions	All groups (CR, CR+PR, PL) significantly (p-0.05) increased bench press strength. CR+PR group significant (p-0.05) greater increase than CR and PL groups.	Both CR and PL groups significantly (p<0.05) increased bench press strength. No significant differences between groups.	Both CR and PL groups significantly (p<0.05) increased bench press strength. No significant differences between groups.		Conclusions	All groups (CR, CR+PR, PL) significantly (p-0.05) increased leg press strength. CR+PR had a significant (p-0.05) greater increase than CR group.	Both CR and PL groups significantly (p<0.05) increased leg press strength. No significant differences between groups.	Both CR and PL groups significantly (p<0.05) increased leg press strength. No significant differences between groups.
Effect on Cr group	↑ 12(3)%	↑ Pre: 76(24)k g Post: 98(26)k g	÷		Effect on Cr group	↑ 12(3)%	↑ Pre: 140(44) kg Post: 190(56) kg	÷
Exercise type, Duration (sessions/week)	Resistance 3s/w	Resistance, 3 s/w	Resistance , 3s/w		Exercise type, Duration (sessions/week)	Resistance 3s/w	Resistance, 3 s/w	Resistance , 3s/w
Placebo (dose per day)	Chocolate and Cherry-flavored sucrose powder =1.2 g/kg	Sucrose Fluor Mixture=0.3g/d 1st 5d followed by 0.07g/d	Sucrose Fluor Mixture=0.3g/d for the first 5d followed by 0.07g/d		Placebo (dose per day)	Chocolate and Cherry-flavored sucrose powder =1.2 g/kg	Sucrose Fluor Mixture=0.3g/d 1st 5d followed by 0.07g/d	Sucrose Fluor Mixture=0.3g/d for the first 5d followed by 0.07g/d
Proteins (dose per day)	Protein= 0.3 g/kg/d	18	1		Proteins (dose per day)	Protein= 0.3 g/kg/d	ц	t
Creatine (dose per day)	CrM= 0.1 g/kg/D	Cr=0.3g/d 1st 5d followed by 0.07g/d	Cr+sucrose=0.3 g/kg/d for the first 5d followed by 0.07 g/kg/d		Creatine (dose per day)	CrM= 0.1 g/kg/D	Cr=0.3g/d 1st 5d followed by 0.07g/d	Cr+sucrose=0.3 g/kg/d for the first 5d followed by 0.07 g/kg/d
Intervention	Creatine + Protein + Training	Creatine + Training	Crreatine + Training		Intervention	Creatine + Protein + Training	Creatine + Training	Crreatine + Training
Duration (weeks)	01	12	12		Duration (weeks)	10	12	12
Population	Older Men	Older Men	Older Men		Population	Older Men	Older Men	Older Men
% males	100%	100%	100%		% males	100%	100%	100%
Sample size	CrP=10 CR=12 PL=12	CR=16 PL=13	CR=16 PL=14	ţţ	Sample size	CrP=10 CR=12 PL=12	CR=16 PL=13	CR=16 PL=14
Mean age (SD)	65.6 (2.7)	70 (6.6)	70.4 (1.6)	ss Streng	Mean age (SD)	65.6 (2.7)	70 (6.6)	70.4 (1.6)
Study	Cando w, 2008	Chilibec k, 2015	Chrusch , 2001	Leg Pre	Study	Cando w, 2008	Chilibec k, 2015	Chrusch 2001

Bench Press Strength

	Conclusions	n CR and PL groups increased dgrip strength. No significant rrences within or between ips.	n CR+PR and PR groups ificantly (p<0.05) increased dgrip strength. No significant srences between groups.	n CR and PL groups ificantly (p<0.05) increased dgrip strength. No significant srences between groups.	n CR and PL groups increased dgrip strength. No significant :rences within or between ips.	group increased Hand Grip ngth while PL group eased. No significant erences within or between ips	roup significantly (p<0.05) eased handgrip strength while
	Effect on Cr group	→ Both han diffe grou	↑ Pre: Both 18.5(8.1 sign)kg han Post: diffe 22.4(9.3)kg	A? Both sign han diffe	→ Both han diffe grou	A Stree decr diffe	↑ Pre: Crg 28.4(0.2 incr
	Exercise type, Duration (sessions/week)	Resistance, 3 s/w	Resistance, 2s/w	D -y	18	1	L
	Placebo (dose per day)	Dextrose=7g/d	Person	Glucose= ?	Cellulose= 20g/d for the first week followed by 5g/d for 7w	Dextrose= 14g on 10d before surgery and 7g/d for 30d after surgery	Flavored effervescent
	Proteins (dose per day)	1	p.	1	ß	1 [°]	в
	Creatine (dose per day)	CrM+dextrose=5g +2g/d	p.,	CR?=0.3g/kg/d during 7d followed by 0.07g/kg/d during the remaining 7 weeks	CrM= 20g/d for the first week followed by 5/d for 7w	CrM+dextrose= 10g+8g d on the 10d before surgery and 5g+4g/d for 30d after surgery	Di-Creatine- Citrate=20g/d
	Intervention	Creatine + Training	Creatine + Protein + Training	Creatine + Training	Creatine	Creatine	Creatine
	Duration (weeks)	14	14	60	œ	9	2
	Population	Older adults	Older adults	QPD	Colorectal Cancer	Total joint arthroplasty	Older subjects
	% males	CR=57% PL=50%	P-1	PL=46%	CR=62,5 % PL=66,7 %	CR=50% PL=42%	47%
Ins	Sample size	CR=14 PL=14	9 PR=7	CR=13 PL=10	CR=16 PL=15	CR=18 PL=19	CR=?
Bilanc di	Mean age (SD)	68.7 (4.8)	70.33 (?)	66 (6.0)	65.1 (12.6)	63.3 (10.2)	74.5 (6.4)
Shilp	Study	Brose 2003	Collins, 2016	Faager, 2006	Norma n, 2006	Roy, 2005	Stout, 2007

Handgrip Strength

Conclusions	CR group significantly (p<0.05) increased LBPP while PL group decreased. No significant differences between groups.	Both CR and PL groups increased LBPP. No significant differences within or between groups.		Conclusions	CR group significantly (p<0.05) increased LBMP while PL group decreased. No significant differences between groups.	CR group increased LBMP while Pl group decreased. No significant differences between groups
Effect on Cr group	↑ Pre: 7.13(1.1 9) Wkg- 1 Post: 7.84(1.2 8) Wkg- 1)	÷		Effect on Cr group	↑ Pre: 5.48(0.9) Wkg-1 Post: 6.18(1.4 4)Wkg-1	· · ←
Exercise type, Duration (sessions/week)	1	i.		Exercise type, Duration (sessions/week)	à	1
Placebo (dose per day)	Celulose powder=0.3 g/kg	Celulose powder=??		Placebo (dose per day)	Celuiose powder=0.3 g/kg	Celulose powder=??
Proteins (dose per day)	1:	LS.		Proteins (dose per day)	31	з
Creatine (dose per day)	CrM= 0.3G/KG	CrM=0.3 g/kg/d		Creatine (dose per day)	CrM= 0.3G/KG	CrM=0.3 g/kg/d
Intervention	Creatine	Creatine		Intervention	Creatine	Creatine
Duration (weeks)	T.			Duration (weeks)	-	a.
Population	Older Men	Older Women		Population	Older Men	Older Women
% males	100%	%0	(LBMP)	% males	100%	%0
Sample size	PL=8	CR=15 PL=12	an Powei	Sample size	CR=10 PL=8	CR=15 PL=12
Mean age (SD)	65.4 (1.5)	63.3 (1.2)	3ody Me	Mean age (SD)	65.4 (1.5)	63.3 (1.2)
Study	Gotshal k, 2002	Gotshal k, 2008	Lower E	Study	Gotshal k, 2002	Gotshal k, 2008

Lower Body Peak Power (LBPP)

Upper Body Peak Power (UBPP))

Conclusions	CR group increased UBPP while PL group decreased. No significant differences within or between groups	Both CR and PL groups increased UBPP. No significant differences within or between groups.
Effect on Cr group	÷	÷
Exercise type, Duration (sessions/week)	1	ä
Placebo (dose per day)	Celulose powder=0.3 g/kg	Celulose powder=??
Proteins (dose per day)	1	(I
Creatine (dose per day)	CrM= 0.3G/KG	CrM=0.3 g/kg/d
Intervention	Creatine	Creatine
Duration (weeks)	1	-
Population	Older Men	Older Women
% males	100%	%0
Sample size	CR=10 PL=8	CR=15 PL=12
Mean age (SD)	65.4 (1.5)	63.3 (1.2)
Study	Gotshal k, 2002	Gotshal k, 2008

Upper Body Mean Power (UBMP)

Conclusions	Both CR and PL groups increased UBMP. No significant differences within or between groups.	Cr group increased UBMP while PL group had no changes. No significant differences within or between groups
Effect on Cr group	÷	÷
Exercise type, Duration (sessions/week)	1	ĩ
Placebo (dose per day)	Celulose powder=0.3 g/kg	Celulose powder=??
Proteins (dose per day)	1	ı
Creatine (dose per day)	CrM= 0.3G/KG	CrM=0.3 g/kg/d
Intervention	Creatine	Creatine
Duration (weeks)	-	-
Population	Older Men	Older Women
% males	100%	%0
Sample size	CR=10 PL=8	CR=15 PL=12
Mean age (SD)	65.4 (1.5)	63.3 (1.2)
Study	Gotshal k, 2002	Gotshal k, 2008

CR, creatine; PL, placebo; PR, protein; CrM, Creatine Monohydrate; CHO, CrM-carbohydrate; COPD, Chronic Obstructive Pulmonary Disease

t Star	nd Test		Solum 9	activities of			, and the second s	Detector	o doce la	Current of Marco	140.04	Canadiant
April	Mean age (SD)	size	% males	Population	Uuration (weeks)	Intervention	(dose per day)	Proteins (dose per day)	Placebo (dose per day)	Exercise type, Duration (sessions/week)	on Cr group	Conclusions
ñete 06	68 (4)	CR=10 PL=6	%0	Older Women	en .	Creatine	CrM=0,3g/kg x3/d for 7d	1	Powdered Cellulose=0.3G/Kg x3/d for 7d	1	č→	Both CR and PL groups decreased time to sit and stand. The decreased was significant (p<0.05) in Cr group. No significant differences between groups.
2002	65.4 (1.5)	CR=10 PL=8	100%	Older Men	Ħ	Creatine	CrM= 0.3G/KG	3	Celulose powder=0.3 g/kg	31	ć.	Both CR and PL groups decreased time to sit and stand. The decreased was significant (p<0.05) in Cr group. No significant differences between groups.
otshal 2008	63.3 (1.2)	CR=15 PL=12	%0	Older Women	-	Creatine	CrM=0.3 g/kg/d	1	Celulose powder=??	L	÷	Both CR and PL groups decreased time to sit and stand. No significant differences within or between groups.
ime-st	tands-te	st										
Study	Mean age (SD)	Sample size	% males	Population	Duration (weeks)	Intervention	Creatine (dose per day)	Proteins (dose per day)	Placebo (dose per day)	Exercise type, Duration (sessions/week)	Effect on Cr group	Conclusions
ollins 2016	70.33 (?)	CR+PR= 9 PR=7	r	Older adults	14	Creatine + Protein + Training	P	n	P++	Resistance, 2s/w	↑Pre: 10(4)rep s Post:14(7)reps	Both CR+PR and PR groups significantly (p<0.05) increased the number of repetitions of sit and stand. No significant differences between groups.
ualan 2014	66.1 (4.8)	CR=15 PL=15 CR+TR= 15 PL+TR=1 55	%0	Vulnerable Older Women	24	Creatine	CrM=20g/d for 5 days followed by single daily dose of 5g	£	Dextrose=20g/da y for 5 days followed by single daily doses of 5g	Resistance, 2 s/w	÷	Both CR and PL groups increased the number of repetitions of sit and stand. No significant differences within or between groups.
bout,	74.5 (6.4)	CR=? PL=?	47%	Older subjects	5	Creatine	Di-Creatine- Citrate=20g/d during for the first week followed by 10g/d	ī	Flavored effervescent powder blend=?	1	÷	Both CR and PL increased the number of repetitions of sit and stand. No significant differences within or between groups.
/ilkins n 2016	63.0 (10.0)	CR=15 PL=20	CR=23% PL= 30%	Rheumatoid Arthritis	12	Creatine	CrM= 20g/d for the initial 5d followed by 3g/d	Ĩ.	Flavored drink powder	a	÷	Both CR and PL increased the number of repetitions of sit and stand. No significant differences within or between groups.

S6- Details regarding functional capacity. Sit Stand Test

Test
9
and
dn
Time

bo Exercise type, Effec r day) Duration on C (sessions/week) grou	Resistance, ↓ Pre 2s/w 7.8(2 s Post 8.7(1. ¹ s	Resistance, 2 🔶 s/w
ns Place er (dose pe	, 70.33(?)	o, 66.1 (4.8)
Proteir iy) (dose p day)	Collins, J. et al 2016	r 5 Gualanc by B. et al se 2014
n Creatine (dose per da	Pu	CrM=20g/d fo days followed single daily do of 5g
Intervention	Creatine + Protein + Training	Creatine
Duration (weeks)	14	24
Population	Older adults	Vulnerable Older Women
% males	r	%0
Sample size	CR+PR= 9 PR=7	CR=15 PL=15 CR+TR= 15 PL+TR=1 5
Mean age (SD)	70.33 (?)	66.1 (4.8)
Study	collins, 2016	Gualan o, 2014

CR, creatine; PL, placebo; CrM, Creatine Monohydrate;

7- Details regarding quality of life, mental and	cognitive outcomes
7- Details regarding quality of life, mental	and
7- Details regarding quality of life,	mental
7- Details regarding quality	of life,
7- Details regarding	quality
7- Details	regarding
	7- Details

	>
	Ħ
	en
1	a
,	₽

	SUC	f s PL+TR os had tions in s when s when or	sed SF-36 (roup had ignificant n or	sed Global ile PL No ences ences	ed oning ad no ificant n or	roups ignificant
	Conclusi	After 24 weeks of intervention, the and CR+TR group significant reduce depression score compared with e PL aroun or the i	CR group decrea scores while PL g no changes. No s differences with between groups	CR group decrea Health status wh group increased significant differ within or betwee	CR group increas emotional functi while PL group h changes. No sign differences withi between groups	Both PL and CR gincreased social functioning. No :
	Outcomes	Geriatric Depression Scale	SF-36 scores	Global health status	Emotional functioning	Social functioning
100 T.	Exercise type, Duration (sessions/week)	Resistance, 2s/w	Č.	1		
And the second se	Placebo (dose per day)	Dextrose= 20g/d for 5d followed by 5g/d	p	Cellulose=20g/d in the first week followed by 10g/d		
	Proteins (dose)	1	15	ε		
1000	Creatine (dose)	CrM=20g/d for 5d followed by 5g/d	Cr=20g/d for 6d followed by 2g/d for 6m and 4g/d	CrM= 20g/d in the first week followed by 10g/d		
10.00	Intervention	Creatine + Training	Creatine	Creatine		
0000	Duration (weeks)	24	96	80		
111000	Population	Older women	Parkinson Disease	Colorectal Cancer		
10.00	% males	%0	CR=71% PL=78%	CR=62,5 % PL=66,7 %		
	Sample size	CR=13 PL=12 CR+TR= CR+TR= 12 PL+TR=1 0	CR=40 PL=20	CR=16 PL=15		
Anno	Mean age (SD)	66.9 (4.9)	60 (9.4)	65.1 (12.55)		
רווב למי	Study	Alves, 2013	Bender 2008	Norma n2006		

and the second design of the s		Cample	% males	Description of		Intervention	Creatine	Proteins	Placeho	Countra time		Conductions
Study	Mean age (SD)	size		ropulation	Uuration (weeks)		(dose)	(dose)	(dose per day)	Exercise type, Duration (sessions/week)	Outcomes	COnclusions
Alves, 2013	66.9 (4.9)	CR=13 PL=12 CR+TR= 12 PL+TR=1	%0	Older women	24	Creatine + Training	CrM=20g/d for 5d followed by 5g/d	t	Dextrose= 20g/d for 5d followed by 5g/d	Resistance, 2s/w	MMSE	CR group increased MMSE while PL group decreased. No significant differences within or between groups. Both CP and Pl groups
		0									3	bour on and rugroups increased BBCS without significant differences within or between groups.
McMor ris, 2007	76.4 (8.48)	CR=15 PL=17	CR=53% PL= 47%	Older subjects	2w	Creatine	PL= 5g/d followed by CrM=5g/d	1	Maxi joule?= 5g/d	E.	Random number generation test	Both CR and PL groups increased RNG without significant differences within or between groups.
											Number recall test forward	Both CR and PL groups increased NRTFN without significant differences
											number Number recall test	within or between groups. Both CR and PL groups increased NRTBN without
											backward number	significant differences within or between groups.
											Number recall test	Both CR and PL groups increased NRTFS without
											forward spatial Number	significant differences within or between groups.
											Number recall test backward spatial	CK group significant (p<0.01) increased NRTBS while PL group significant decreased (p<0.05)
											Long term memory test	CR group significant (p<0.01) increased LTMT while PL group decreased
Norma n2006	65.1 (12.55)	CR=16 PL=15	CR=62,5 % PL=66,7 %	Colorectal Cancer	ø	Creatine	CrM= 20g/d in the first week followed by 10g/d	L	Cellulose=20g/d in the first week followed by 10g/d	đ	Cognitive functioning	CR group had no changes on cognitive functioning while PL group increased it. No significant differences within or between groups.
												-

		Q	ant s.	TT.		°°	rs Sed	01) bup tes cant		· · · · · · · · ·	.⊆	Se
		Conclusions	Both PL and CR groups significantly (p<0.01) increased ESWT. No signific differences between group	Both groups increased ESW The increased was significa (p<0.01) in CR group. No significant differences between groups.		Conclusions	Both PL and CR groups increased FFM. The increas was significant (p<0.01) in (group. No significant differences between group	CR group significantly (p<0. increased FFM while PL gro decreased it. The differenc between groups are signifi (p<0.05).		Conclusions	Both PL and CR groups decreased FM with no significant differences with or between groups.	Both groups decreased FM with no significant differen within or between groups.
		Effect on Cr group	↑377.4 (257.7)s	↑Pre: 320.2 (202.4)s Post: 514.9(3 81.9)s		Effect on Cr group	↑ 0.9(1.6) kg	↑2.0 (1.9) kg		Effect on Cr group	÷	÷
		Exercise type, Duration (sessions/week)	Pulmonary rehabilitation, 21 s/7w	Pulmonary Rehabilitation, 2 s/w		Exercise type, Duration (sessions/week)	Pulmonary rehabilitation, 21 s/7w	Pulmonary Rehabilitation, 2s/w		Exercise type, Duration (sessions/week)	Pulmonary rehabilitation, 21 s/7w	Pulmonary Rehabilitation, 2s/w
		Placebo (dose per day)	Lactose=24g/d for 5d followed by 4g/d during pulmonary rehabilitation	Glucose= ?		Placebo (dose per day)	Lactose=24g/d for 5d followed by 4g/d during pulmonary rehabilitation	Glucose polymer= 40.7g 3xday for 14 days followed by 40.7g 1xday for 10 weeks		Placebo (dose per day)	Lactose=24g/d for 5d followed by 4g/d during pulmonary rehabilitation	Glucose polymer= 40.7g 3xday for 14 days followed by 40.7g 1xday for 10 weeks
		Proteins (dose per day)	18.	1		Proteins (dose per day)	L.	ı		Proteins (dose per day)	1	T
		Creatine (dose per day)	CrM=22g/d for 5d followed by 3.76g/d <mark>d</mark>	CR?=0.3g/kg/d for 7d followed by 0.07g/kg/d		Creatine (dose per day)	CrM=22g/d for 5d followed by 3.76g/d	CrM + glucose= 5g+35g 3xday for 14 days followed by 5g+35 1x/d		Creatine (dose per day)	CrM=22g/d for 5d followed by 3.76g/d	CrM + glucose= 5g+35g 3x/d for 14 days followed by 5g+35 1x/d
		Intervention	Creatine + Training	Creatine + Training		Intervention	Creatine + Training	Creatine + Training		Intervention	Creatine + Training	Creatine + Training
		Duration (weeks)	7	60		Duration (weeks)	7	12		Duration (weeks)	7	12
variables.	SWT)	Population	COPD	СОРD		Population	COPD	СОРД		Population	COPD	сорр
COPD	ng Test (E	% males	CR=50% PL=74%	CR=46% PL=40%		% males	CR=50% PL=74%	r		% males	CR=50% PL=74%	n
garding	tle Walkin	Sample size	CR=38 PL=42	CR=13 PL=10	(M)	Sample size	CR=38 PL=42	CR=14 PL=11		Sample size	CR=38 PL=42	CR=14 PL=11
etails re	nce Shut	Mean age (SD)	68.2 (8.2)	66.0 (6.0)	e Mass (F	Mean age (SD)	68.2 (8.2)	61.7 (8.0)	ss (FM)	Mean age (SD)	68.2 (8.2)	61.7 (8.0)
S8- D	Endura	Study	Deacon , 2008	Faager, 2006	Fat Free	Study	Deacon , 2008	Fuld, 2005	Fat Mas	Study	Deacon , 2008	Fuld, 2005

CR, creatine; PL, placebo; PR, protein; CrM, Creatine Monohydrate; CHO, CrM-carbohydrate; COPD, Chronic Obstructive Pulmonary Disease

variables.
Parkinson
regarding
- Details
6

S9- Det	ails reg	arding P	arkins	on variable	es.							
Parkinso	n Variab	les										
Study	Mean age (SD)	Sample size	% males	Population	Duration (weeks)	Intervention	Creatine (dose per day)	Proteins (dose per day)	Placebo (dose per day)	Exercise type, Duration (sessions/week)	Outcomes	Conclusions
Bender, 2008	60 (9.4)	CR=40 PL=20	CR=71 % PL=78 %	Parkinson Disease	96	Creatine	Cr=20g/d for 6d followed by 2g/d for 6m and 4g/d	Ď	Pro	E	Total striatal 1231-FP-CIT uptake	Both groups decreased Total striatal 1231-FP-CIT uptake without significant differences within or between groups
											SPECT variableS	No overall treatment effect
										(0	UPDRS scores	Both groups increased UPDRS scores without significant differences within or between groups
										-	Agonist dose	Both groups significant(p<0.05) increased agonist dose. No significant differences
											Levodopa dose	Both groups increased levodopa doses without significant differences within or between groups
Hass, 2007	68.1(3 .8)	CR=10 PL=10	85%	Parkinson Disease	12	Creatine + Training	CrM= 20g for the first 5d followed by 5g/d	1	Lactose Monohydrate= 20g for the first 5d followed by 5g/d	Resistance Training=2 sessions/w	UPDRS total UPDRS	Cr group significant (p<0.05) decreased UPDRS total while PL group significantly (p<0.05) increased Both groups significantly
											UPDRS ADL	(p-0.05) decreased 0-0.05 mental Both groups significantly (p<0.05) decreased UPDRS
											UPDRS motor	Cr group significant (p<0.05) decreased UPDRS motor while PL group significantly (p<0.05) increased

CR, creatine; PL, placebo; CrM, Creatine Monohydrate; UPDRS, Unified Parkinson's Disease Rating Scale, ADL, Activity of Daily Living

		ma ificant	u	ut ups.	E te	uo	a urea.	group thin or	een	ma ficant	BUN.	tinine een	It
	Conclusions	CR group significantly (p<0.05) increased plas creatinine, while PL group decreased. No sign differences between proups	CR group significantly (p<0.05) increased urin creatine, while PL group had no changes. No significant differences between groups.	Both groups increased urine creatinine witho significant differences within or between grou	Cr group significantly (p<0.05) increased Cr:C ratio, while PL group decreased. No significan differences between groups.	Both CR and PL groups presented no changes plasma Creatinine.	Both groups presented no changes on plasma	CR+PR increased plasma creatinine while PR had no changes. No significant differences wi between groups	Both CR+PR and PR groups increased plasma with no significant differences within or betw groups	CR group significantly (p<0.05) increased plas creatinine while PL group decreased. No signi changes between groups.	Both groups presented no changes on plasma	Both CR and PL groups increased plasma crea with no significant differences within or betw groups	Both groups decreased BUN with no signification
	Effect on Cr group	ΦPre: 111.4(24.4)μ mol/L Post: 1262(33.4)μmol/L	•Pre: 0.9(0.4)mg/mL Post: 1.0(0.4)mg/mL	4	†Pre: 0.89(0.73) Post: 2.13(1.97)	0	0	÷	÷	↑ Pre: 89.4(15.7)µmol/l Post: 97.9(17.8)µ mol/l	0	÷	→
	Outcomes	Plasma creatinine	Urine Creatine	Urine Creatinine	Urine Cr:Crn ratio	Plasma creatinine	Plasma urea	Plasma creatinine	Plasma urea	Plasma creatinine	BUN	Plasma creatinine	BUN
	Exercise type, Duration (sessions/	week) Resistanc e, 3 s/w				12		Resistanc e, 2s/w		E)		10	•
	Placebo (dose per day)	Dextrose= 7g/d				Powdered Cellulose= 0.3g/Kg	x3/d	¢.,		Cellulose powder=0 .3 g/kg		Cellulose powder=?	
	Proteins (dose per day)					0		с.,		c.		r.	
	Creatine (dose per day)	CrM+de xtrose= 5e+2ø/d	i P			CrM=0,3 g/kg x3/d for	7d	r.,		CrM= 0.3g/Kg		CrM=0.3 g/kg/d	
	Interv ention	Creati ne + Traini	BL			Creati ne		Creati ne + Protei	n + Traini ng	Creati ne		Creati ne	
	Duration (weeks)	14						14		-		-	
tery issues	Population	Older adults				Older Women		Older adults		Older Men		Older Women	
ung Sa	% males	CR=57 % PI=50	*			%0		~ .		100%		%0	
s regard	Sample size	CR=14 PL=14				CR=10 PL=6		CR+PR= 9 PR=7		CR=10 PL=8		CR=15 PL=12	
	Mean age (SD)	68.7 (4.8)				68 (4)		70.33 (?)		65.4(1 .5)		63.3 (1.2)	
-010	Study	Brose , 2003				Cañet e, 2006		Collin 5, 2016		Gotsh alk, 2002		Gotsh alk, 2008	

0.22	Ibumin and PL vithin or	e PL decreased. tween groups.	PL decreased. tween groups.	up increased. tween groups.	plasma Brb or between	AST with no ten groups.	AST with no sen groups.	group within ar	roup decreased. etween groups.	p increased. No een groups.	gnificant	up increased. No sen groups.	vhile PL group /ithin or between
Conclusions	CR group had no changes on plasma a increased. No significant differences v between groups.	CR group had no changes on AST while No significant differences within or be	Cr group had no changes on ALT while No significant differences within or be	CR group decreased GGT while PL gro No significant differences within or be	Both CR+PR and PR groups decreased with no significant differences within groups.	Both CR+PR and PR groups decreased significant differences within or between	Both CR+PR and PR groups increased. significant differences within or betwe	CR+PR group increased GGT while PR decreased. No significant differences between groups.	CR+PR group increased ALP while PL g No significant differences within or b	Cr group decreased AST while PL grou significant differences within or betw	Both groups decreased ALT with no si differences within or between groups	CR group decreased GGT while PL gro significant differences within or betwe	CR group decreased plasma albumin v increased. No significant differences v
Effect on Cr group	0	0	0	÷	÷	÷	÷	÷	÷	÷	÷	÷	÷
Outcomes	Albumin	AST	ALT	GGT	Bilirrubin	AST	ALT	GGT	ALP	AST	ALT	GGT	Albumin
Exercise type, Duration (sessions/week)	1				Resistance, 2s/w					1			
Placebo (dose per day)	Powdere d Cellulose	=0.3G/K g x3/d for 7d			n.					Celulose powder= 0.3g/kg			
Proteins (dose per day)	ä				0-					1			
Creatine (dose per day)	CrM=0,3g/ kg x3/d for 7d				0					CrM=0.3 g/kg/d			
Interv ention	Creati ne				Creati ne + Protei	n + Trainin				Creati ne			
Duration (weeks)	-				14					-			
Population	Older Women				Older adults					Older Men			
% male s	%0				n.					100 %			
Sample size	CR=10 PL=6				CR+PR=9 PR=7					CR=10 PL=8			
Mean age (SD)	68(4)				70.33(?)					65.4(1. 5)			
Study	Cañete 2006				Collins, 2016					Gotshalk 2002			

		Wor	len		Je e	g/kg/d		powder=	l.	ą	÷	ur group decre significant diffe	sed Aol while PL rences within or b	group muteaseu. Iv etween groups.
										ALT	<	Cr group increa significant diffe	sed ALT while PL g rences within or b	roup decreased. N etween groups.
										GGT	<	Cr group increa significant diffe	sed GGT while PL, rences within or b	group decreased. etween groups.
effects														
le % males Populati	es Populatio	pulatio	5	Duration (weeks)	Interv	/ention	Creatine (dose per day)	Proteins (dose per day)	Placebo (dose per day)	Exercise type, Duration (sessions/week)	Adverse effe	ct reported	Number of reports on Cr group	Number of reports on CPL group
CR=57% Older adu PL=50%	% Older adu	ler adu	12	14	Creatir Trainin		CrM+dextros e=5g+2g/d	1	Dextrose=7g/d	Resistance, 3 s/w	Gastrointestir	nal distress	1	
0 100% Older Me	Older Me	ler Me	ç	10	Creatir Proteir Trainin	+ +	CrM= 0.1 s/kg/D	Protein= 0.3 g/kg/d	Chocolate and Cherry-flavored sucrose powder =1.2 g/kg	Resistance 3s/w	Muscle soren stiffness	ess and	1	2
100% Older Me	Older Me	ler Me	e	12	Creatii Trainir		Cr=0.3 g/kg/d for the first 5 d ollowed by 1.07 g/kg	9	Sucrose Fluor Mixture=0.3g/d first 5d followed by 0.07g/d	Resistance, 3s/w	Loose stool, n cramping, mu strain.	nuscle Iscle pull or	ŧ	÷
100% Older Me	Older Me	ler Me	c	e	Creati	e	0.3G/KG	ī	Celulose powder=0.3 g/kg	1	"There were r significant diff between grou pressure and scores for mu cramps, gastr distress, and	no fferences ups in blood Likert iscle ointestinal well-being"	D:	n .
100% Older Me	Older Me	ler Me	c.	4	Creati	2	CrM + dextrose= 1005+28g/d Juring 10 13v5, ollowed by ig+6.8g	1	Dextrose= 25g/d for 10d followed by 20g	3	Gastrointestri disconfort	e	1	0
											Skin rash			0
											Muscle cramp plantar flexor	ping of the s	1	0